

HCTM PPUKM Surgical Prophylaxis Guide 2018

1st Edition



Published by: Antimicrobial stewardship committee HCTM UKM

Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia Jalan Yaakob Latif, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur Tel: +603-9145 5001/ 5079

Copyright

The copyright owner of this publication is Antimicrobial stewardship committee UKMMC. Content may be reproduced in any number of copies and in any format or medium provided that a copyright acknowledgement to Antimicrobial stewardship committee UKMMC is included and the content is not changed, not sold, nor used to promote or endorse any product or service and not used inappropriately or misleading context.

ISBN 978-967-16406-0-9



ISBN:

STATEMENT OF INTENT

These guidelines update the previous guidelines developed in 2012. The content of the guideline is developed based on the best practice and also the latest evidence available. Any deviation from the recommendation in this guideline should be done with justification and evidence based.

This guideline will be reviewed again in 2020.

Forewords

Dr Petrick @Ramesh K Periyasamy

It has been a few years since the last antibiotics guidelines have been updated. There is a serious need to do this as bacteria becomes more resistant with multiple and broader antibiotics usage and duration.

With that in mind, we have decided to update the guidelines based not only with local and international guidelines but also with expertise from a team of specialists. It's been a daunting but fruitful task.

A very special thanks goes to the pharmacy department who had worked tirelessly in bringing everybody together to check on all the recommendations.

Truly we hope that the guidelines will be used as it mirrors the latest recommendations with local available drugs.

With its usage, it is our hope, that antibiotic appropriateness will improve and duration of prophylaxis will be short as recommended.

Broader choice of antibiotic prophylaxis and prolong antibiotic duration has been shown to be ineffective and increases surgical site infection with possible risk of multiple resistant organisms.

With that, I would like to thank everyone in this task force and may this guide will be used in antimicrobial stewardship for all intents and purposes.

PROTOCOL DEVELOPMENT AND OBJECTIVES

The main aim of the guidelines is to guide practitioner on the current evidence and to promote judicious use of prophylactic antibiotic use in the prevention of oral surgical site infections

SPECIFIC OBJECTIVES

- 1. To identify the surgical procedures that would benefit from surgical antibiotic prophylaxis.
- 2. To guide the choice and duration of prophylaxis based on the latest evidence available.

Contents

| Mem | nbers of protocol development | 6 |
|-------|--|----|
| Princ | ciple of Surgical Antibiotic Prophylaxis | 7 |
| Bene | efits of prophylaxis | 9 |
| Side | effects of Antibiotics and Antibiotic allergy | 10 |
| ANTI | BIOTIC PROPHYLAXIS ACCORDING TO DISCIPLINES | 11 |
| 1. | NEUROSURGICAL PROCEDURES | 12 |
| 2. | OPHTHALMOLOGY PROCEDURES | 13 |
| 3 | ENT PROCEDURES | 16 |
| 4. | MAXILLOFACIAL PROCEDURES | 24 |
| 5. | BREAST & ENDOCRINE PROCEDURES | 31 |
| 6. | CARDIOTHORACIC PROCEDURES | 36 |
| 7. | VASCULAR PROCEDURES | 37 |
| 8. | UPPER GI & BARIATRIC PROCEDURES | 39 |
| 9. | COLORECTAL PROCEDURES | 41 |
| 10. | HEPATOBILIARY PROCEDURES | 44 |
| 11. | UROLOGY PROCEDURES | 46 |
| 12. | OBSTETRICS AND GYNAECOLOGY | 48 |
| 13. | ORTHOPEDIC PROCEDURES | 55 |
| 14. | PAEDIATRIC SURGERY | 58 |
| 15. | INTERVENTIONAL RADIOLOGY | 63 |
| Timiı | ng of administration preoperative and intraoperative Surgical Antibiotic Prophylaxis | 66 |
| Half- | life of and proposed redosing interval of antibiotic | 67 |
| Dura | tion of Surgical Antibiotic Prophylaxis | 68 |
| Impl | ementing the guideline | 69 |
| Surgi | ical Procedures and Common Organisms | 70 |
| Antik | piotic Spectra among common clinical isolates | 72 |

Members of Protocol Development

| Chairmannan | Co Chairmannan |
|--|---|
| Chairperson | Co-Chairperson |
| Ass. Prof Dato'Dr. Razman Jarmin | Dr Petrick Periyasamy |
| Member | |
| Prof. To' Puan Dr Nordiah Hj Awang Jalil | Assoc Prof Dr.Ramliza Ramli |
| Lau Chee Lan | Assoc Prof Dr Isa Naina Mohamed |
| Department of surgery | Department of ENT |
| [Neurosurgery] | Dr (Mr) Kong Min Han |
| Assoc. Prof. Dr. Azizi Abu Bakar | Dr (Miss) Farah Dayana Zahedi |
| | |
| Assoc. Prof Dato' Dr Jegan A/L Thanabalan | Prof Dato' Dr Abdullah Sani Mohamad |
| | Prof. Dr Goh Bee See |
| [Breast & Endocrine] | |
| Prof Dr Rohaizak Muhammad | Department of Ophthalmology |
| Prof Dr Norlia Abdullah | Assoc Prof Dr Norshamsiah Md Din |
| [Cardiothoracic] | Department of Maxillofacial |
| Dr (Mr) Muhammad Hishamuddin bin Ismail | Dr Rifgah Nordin |
| Prof Dato' Sri Dr Mohd Ramzisham Abdul Rahman | Dr Fadzlina Abd Karim |
| [Upper Gastrointestinal & Bariatric] | Department of O&G |
| Dr(Miss) Reynu Rajan | Assoc Prof Dr Mohamed Nasir Shafiee |
| Prof Dato' Dr Nik Ritza Kosai | Dr Aida Hani Mohd Kalok |
| Tron baco Britim Milita Nosar | Dr Anizah Ali |
| [Vascular] | Prof. Dr. Mohamed Hashim Omar |
| Assoc. Prof. Dr. Mohamad Azim Mohd. Idris | |
| Miss(Dr) Lenny Suryani Binti Safri | Department of Orthopaedic |
| Wilss(Di) Lettiny Suryani Biliti Sani | Dr. (Mr) Ahmad Farihan Bin Mohd Don |
| [Henatohilian/] | Assoc Prof Dr. Abdul Halim Abdul Rashid |
| [Hepatobiliary] | |
| Dr (Mr) Zamri Zuhdi | Department of Radiology |
| Assoc. Prof Dato' Dr Razman Jarmin | Assoc Prof Dr Nur Yazmin Binti Yaacob |
| [Colorectal] | |
| Dr (Mr) Zamri Zuhdi | Department of Anaesthesiology |
| Assoc Prof Datuk Dr Ismail Sagap | Dato' Dr Wan Rahiza Wan Mat |
| | Assoc Prof Dr Raha Abdul Rahman |
| [Urology] | A3300 FIOI DI Nalia Abdul Nalililali |
| Ass. Prof Goh Eng Hong | |
| Lt Kol (PA) Prof. Dato' Dr Zulkifli Md Zainuddin | |
| [Paediatric Surgery] | |
| Prof Dr Dayang Anita Abdul Aziz | |
| Froi Di Dayang Anila Abuul Aziz | |
| | |

Contributors

Assoc Prof (Clinical) Dato' Dr Oteh Maskon (Head of Cardiology Unit) Dr. Ruslinda Mustafar (Head of Nephrology Unit) Assoc. Prof Dr. Rozman Bin Zakaria (Radiologist)

Pharmacy Department

Dato' Faridah Md Yusof
Chloe Chua Xin Yun
Farah Waheeda Tajurudin
Ghan Sheah Lin
Kong Shue Hong
Loong Lysia
Lydia Gan Lay Yen
Michelle Tan Hwee Pheng
Nur Jannah Azman
Pau Kiew Bing
Sarah Anne Roberts
Yin Mei Kuen

Principle of Surgical Antibiotic Prophylaxis

Razman Jarmin & Chee Lan Lau

Antimicrobial prophylaxis is part of the important measures to minimize risk surgical site infection (SSI), by reducing the bacterial load at the incision site. The choice of antibiotic should be targeted at the most common but not all possible microorganisms according to surgical procedure(s). The benefit of administration antibiotics should outweigh the probability of adverse drug reaction, super-infection or resistance development.

Surgical Wound classification

According to CDC, surgical wounds are categorised into 4 classes:

| Wound class | Description |
|-----------------------|--|
| 1. Clean | An uninfected operative wound in which no inflammation is encountered and the respiratory, alimentary, genital, or uninfected urinary tracts are not entered. In addition, clean wounds are primarily closed and, if necessary, drained with closed drainage. Operative incisional wounds that follow nonpenetrating (blunt) trauma should be included in this category if they meet the criteria. |
| 2. Clean-Contaminated | Operative wounds in which the respiratory, alimentary, genital, or urinary tracts are entered under controlled conditions and without unusual contamination. Specifically, operations involving the biliary tract, appendix, vagina, and oropharynx are included in this category, provided no evidence of infection or major break in technique is encountered. |
| 3. Contaminated | Open, fresh, accidental wounds. In addition, operations with major breaks in sterile technique (for example, open cardiac massage) or gross spillage from the gastrointestinal tract, and incisions in which acute, nonpurulent inflammation is encountered, including necrotic tissue without evidence of purulent drainage (for example, dry gangrene), are included in this category. |
| 4. Dirty or Infected | Includes old traumatic wounds with retained devitalized tissue and those that involve existing clinical infection or perforated viscera. This definition suggests that the organisms causing postoperative infection were present in the operative field before the operation. |

The prevalence of surgical site infections (SSI) is attributed to multiple factors such as infection control measures, surgical technique, environment, perioperative preparation and etc. Antibiotic prophylaxis is justified in high risk patient with the following conditions:

| • | Extremes of age | • | Diabetes mellitus |
|---|------------------------------|---|-----------------------------|
| • | Poor nutritional status | • | Immunocompromised |
| • | Obese | • | Corticosteroid therapy |
| • | Tobacco use | • | recent surgical procedure |
| • | Concurrent remote infections | • | Microorganisms colonization |

Antimicrobial prophylaxis is indicated for most clean-contaminated and contaminated procedures, and certain clean procedures considering the infection risk and morbidity. Use of antimicrobials in dirty procedures or infection is not a prophylaxis measure but treatment.

Reference:

- Surgical Site Infection (SSI) Event: Centre for Disease Control. 2018. https://www.cdc.gov/nhsn/PDFs/pscManual/9pscSSIcurrent.pdf. Updated January 2018. Accessed March 3, 2018.
- 2. Bratzler et al. 2013. Clinical practice guidelines for antimicrobial prophylaxis in surgery. American journal of health-system pharmacy. 2013;70:195-283.

Benefits of prophylaxis

Zamri Zuhdi

The benefits of antibiotic prophylaxis is related to the consequence of severity of SSI¹.

- 1. Reduce mortality and morbidity: for example in cases involving anastomosis of bowel therefore it reduce or minimalized post-operative anastomotic leak².
- 2. Reduce hospital cost: because of reduce unnecessary expensive antibiotics due to prolonged of surgical site infection².
- 3. Reduce hospital stay for the patient: its mean the patient will discharge on time for example in laparoscopic cholecystectomy, total hospital stay only 3 days².
- 4. Reduce side effect of multiple drug: because of practising using single dose of antibiotic therefore reduce the total amount of antibiotic used³.

References:

- 1. Mark J. Enzler et al; Antimicrobial prophylaxis in adult, Mayo Clin. Pre.;2011,86(7); 686-701
- 2. A National Clinical Guideline; Antibiotic Prophylaxis in Surgery; Scottish Intercollegiate Guidelines Network no. 45; July 2000
- 3. Ongom and kilijjambu; Org Process Res, 2013,1:3

Side effects of Antibiotics and Antibiotic allergy

Isa Naina Mohamed

Selection of antibiotic prophylaxis must cover expected pathogen at surgical site and should take into account of local resistance patterns. Cross-reactivity between penicillins and cephalosporins is generally quoted at 10%. This reflects data collected prior to 1980, and is confounded by the impurity of the antibiotics in use and tends to overestimate cross sensitivity. Cross-reactivity between penicillins and second generation cephalosporins is low. (Pichichero ME, 2005) Skin test allergy test may be performed to confirm cross-reactivity or when patients are not sure on their allergy history. Allergy history to any drug especially antibiotics must be elicited prior to any commencement of prophylactic or therapeutic antibiotics.

Allergy to antibiotic

Patients with a history of anaphylaxis, laryngeal oedema, bronchospasm, hypotension, local swelling, urticaria or pruritic rash, occurring immediately after a penicillin therapy are at an increased risk of immediate hypersensitivity to beta-lactams and should not receive prophylaxis with a beta-lactam antibiotic. In an event of uncertainty regarding cross-reactivity, and due to the severity of anaphylactic reactions, patients with a history of anaphylaxis to penicillins should not be prescribed Cephalosporins.

Antibiotic associated diarrhoea and clostridium difficile infection

The risk of contracting CDI is raised for patients who:

- have current or recent use of antimicrobial agents (especially broad spectrum antibiotics)
- are elderly
- have a serious underlying illness that compromises their immune system
- have a prolonged stay in a healthcare setting
- have recently had gastrointestinal surgery
- are in hospital when there is an outbreak of CDI
- are using a proton pump inhibitor.

It is not clear how many patients develop CDI following antibiotic prophylaxis with rates of 0.2% to 8% reported depending on the type of surgical procedure involved. (Southern WN et al, 2010) The prevalence of CDI is related to a number of factors including total antibiotic usage and, in particular, to the use of third generation cephalosporins. (Wilcox MH et al. 1996, Wilcox MH et al. 1998, Zadik PM et al. 1998). There is evidence that multiple doses of cephalosporins increase the risk of CDI more than a single dose. In a study of over 1,800 patients undergoing surgery for hip fracture, a change of antibiotic policy from using three doses of prophylactic cefuroxime (1.5 g) to one single dose of cefuroxime (1.5 g) with gentamicin (240mg) resulted in a decrease in CDI from 4.2% to 1.6% (p=0.009). (Starks I et al. 2008)

In patients requiring antibiotic prophylaxis, the risk of *Clostridium difficile* infection should always be considered. The higher risk of *Clostridium difficile* infection associated with some antibiotics (cephalosporins, fluoroquinolones, clindamycin, carbapenems) should also be taken into account when prescribing.

References

- Pichichero ME. A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients. Pediatrics. 2005;115(4 Part 1):1048-57.
- 2. Wilcox MH, Cunniffe JG, Trundle C, Redpath C. Financial burden of hospital-acquired *Clostridium difficile* infection. J Hosp Infect 1996;34(1):23-30.
- 3. Wilcox MH, Smyth ET. Incidence and impact of *Clostridium difficile* infection in the UK, 1993-1996. J Hosp Infect 1998;39(3):181-7.
- 4. Zadik PM, Moore AP. Antimicrobial associations of an outbreak of diarrhoea due to *Clostridium difficile*. J Hosp Infect 1998;39(3):189-93.
- 5. Starks I, Ayub G, Walley G, Orendi J, Roberts P, Maffulli N. Single-dose cefuroxime with gentamicin reduces *Clostridium difficile*-associated disease in hip-fracture patients. J Hosp Infect 2008;70(1):21-6.

ANTIBIOTIC PROPHYLAXIS ACCORDING TO DISCIPLINES

1. NEUROSURGICAL PROCEDURES

| NEUROSURGICAL PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION [FROM INCISION] | REFERENCES | REMARKS |
|------------------------------------|--|--|-----------------------------|-----------------------------------|------------------|
| Clean (Craniotomy, burrhole | IV Cefazolin 2g | If beta lactam allergy | IntraOP : | National Antibiotic | |
| for clean pathology) | or | IV Clindamycin 900mg | Cefazolin or | Guideline 2014 2 nd Ed | |
| | IV Cefuroxime 1.5gm | | cefuroxime q4hrly | Liu W et al 2014. Clin | |
| Clean + Implant (CSF diversion | | If colonize with MRSA | | Neurol Neurosurg. | |
| procedures e.g. Shunt, EVD, | | IV Vancomycin 1g or 15mg/kg | Post Op: q8hrly up | Jan;116:13-9 | |
| Omaya, DBS, Titanium/acrylic, | | in 200mL over 2 hrs. | to 24 hours | | |
| craniplasty, artificial dura used) | | | 24 Hours | | |
| Clean contaminated | | | | | |
| (Transphenoidal, Acosutic | | | | | |
| neuroma, involving air sinuses) | | | | | |
| Contaminated (Skull fracture, | IV Cefuroxime 1.5gm q8h | If beta lactam allergy | For 72 hours | Ratilal et al 2015. | To review |
| previous surgery, lacerated | +/- | Clindamycin 900mg IV | | Cochrane Database of | antibiotic if no |
| scalp) | IV Metronidazole 500mg q8h | | | Systematic Reviews | improvement |
| | | If colonize with MRSA | | Rosen et al. 2016 Am J | after 3 days |
| | add IV gentamicin 2mg/kg if | IV Vancomycin 1g or 15mg/kg | | Rhinol Allergy (30) e10 – | |
| | soiling present | in 200mL over 2 hrs. | | e16 | |
| Transnasal surgery | IV Cefazolin 1-2 g | If beta lactam allergy | IntraOP: | | |
| | | IV Clindamycin 900mg | Cefazolin or | | |
| | OR | | cefuroxime q4hrly | | |
| | N/Cof as invades | If colonize with MRSA | Deal Consolidation | | |
| | IV Cefuroxime 1.5g + IV Metronidazole 500mg | IV Vancomycin 1g or 15mg/kg in 200mL over 2 hrs. | Post Op: q8hrly up | | |
| | + IV Wetromazole Soonig | iii 200iii over 2 iiis. | 24 hours | | |
| | | | 27 HOUIS | | |
| Implantation of intrathecal | IV Cefazolin 2g | If beta lactam allergy | To consult specialist | | To be |
| pump | - 5 | IV Clindamycin 900mg | | | reviewed by |
| | OR | , , | | | specialist after |
| | | If colonize with MRSA | | | 3 days |
| | IV Cefuroxime 1.5g | IV Vancomycin 1g or 15mg/kg | | | |
| | | in 200mL over 2 hrs. | | | |

OPHTHALMOLOGY

2. OPHTHALMOLOGY PROCEDURES

| OPHTHALMOLOGY PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|---|--|--|--|--|---------|
| All types of ocular surgeries | Topical ciprofloxacin, chloramphenicol or levofloxacin | Any of the listed drugs | At completion of surgery | 2017 Clinical practice guideline on management of postoperative infectious endophthalmitis | |
| Cataract surgery - uncomplicated | Intracameral cefuroxime 1 mg/0.1 ml | Subconjunctival gentamicin | At completion of surgery | | |
| Cataract surgery – complicated (with posterior capsular rent) | Subconjunctiva Gentamicin and oral ciprofloxacin 500 mg bd | None | At completion of surgery | | |
| Anterior chamber washout | Subconjunctiva Gentamicin | None | At completion of surgery | | |
| Pterygium excision with bare sclera | Subconjunctiva Gentamicin | None | At completion of surgery | | |
| Trabeculectomy | Subconjunctiva Gentamicin | None | At completion of surgery | Wallin, Ö et al. (2014) Acta ophthalmologica, 92(5), 426-431. | |
| Implantation of glaucoma drainage device | Subconjunctiva Gentamicin | None | At completion of surgery | | |
| Goniotomy | Subconjunctiva Gentamicin | None | At completion of surgery | | |
| Penetrating keratoplasty/ other corneal transplants | Subconjunctiva Gentamicin | None | At completion of surgery | Ang, M et al. (2012 Ophthalmology, 119(11), 2239- 2244. | |
| Lamellar keratoplasty | Subconjunctiva Gentamicin | | At completion of surgery | Melles, Get al. (2000). Ophthalmology, 107(10), 1850- 1856. | |
| Osteoordontokeratoplasty (ookp) | IV Co-AmoxiClav1.2 g then PO Co-AmoxiClav625 mg bd | IV Ciprofloxacin 400 mg then PO Ciprofloxacin 500mg bd | IV 1 dose at induction then at completion of surgery | | |

| OPHTHALMOLOGY PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|-------------------------------|--|--------------------------------------|--------------------------|---|---------|
| Ptosis repair | Ointment <i>Maxitrol</i> ® (neomycin and polymyxin B sulfates and dexamethasone) | None | At completion of surgery | | |
| Surgical correction of squint | Ointment <i>Maxitrol</i> ® (neomycin and polymyxin B sulfates and dexamethasone) | None | At completion of surgery | Mojon, D. S. (2009). Ophthalmologica, 223(2), 111- 115. | |
| Intravitreal injection | Topical ciprofloxacin | None | After injection | De Caro, et al (2008).Retina, 28(6), 877-883. | |
| Removal of Silicone Oil | Subconjunctiva Gentamicin | None | At completion of surgery | Dada, V. Ket al (2001) Journal of Cataract & Refractive Surgery, 27(8), 1243-1247. | |
| Scleral buckling | Subconjunctiva Gentamicin Oral Ciprofloxacin 500 mg bd | Oral Cefuroxime, Oral Cloxacillin | At completion of surgery | Chhablani et. Al. (2013). Journal of ophthalmic inflammation and infection, 3(1), 67. | |
| Vitrectomy | Subconjunctiva Gentamicin | None | At completion of surgery | Yang, S. S., & Jiang, T. (2013). International Journal of ophthalmology, 6(2), 198 | |
| Eyelid reconstruction | Ointment Maxitrol® (neomycin and polymyxin B sulfates and dexamethasone) | None | At completion of surgery | Karcioglu, Z. A. (Ed.). (2014). Springer. | |
| Exenteration | Ointment <i>Maxitrol</i> * (neomycin and polymyxin B sulfates and dexamethasone) | None | At completion of surgery | Karcioglu, Z. A. (Ed.). (2014Springer. | |
| Enucleation | Ointment <i>Maxitrol</i> * (neomycin and polymyxin B sulfates and dexamethasone) | None | At completion of surgery | Iordanidou, V., & De Potter, P. (2004). American journal of ophthalmology, 138(3), 425-429. | |
| Orbital decompression | Ointment <i>Maxitrol</i> (neomycin and polymyxin B sulfates and dexamethasone) | None | At completion of surgery | Woo, K. I., & Kim, Y. D. (2004). Japanese journal of ophthalmology, 48(4), 397-403. | |
| Orbital floor repair | Ointment <i>Maxitrol</i> ° (neomycin and polymyxin B sulfates and dexamethasone) | None | At completion of surgery | Wladis, E. J. (2013). Orbit, 32(1), 30-32. | |
| Reconstruction of socket | Ointment <i>Maxitrol</i> (neomycin and polymyxin B sulfates and dexamethasone) | None | At completion of surgery | Karcioglu, Z. A. (Ed.). (2014). Springer. | |

2 A.POTENTIAL CONTAMINATED SURGERIES (THERAPEUTIC PURPOSES)

OPHTHALMOLOGY

[¥] = potential contamination depending on the reason for evisceration e.g uncontrolled endophthalmitis or panophthalmitis

| OPHTHALMOLOGY | PREFERRED FIRST LINE | ALTERNATIVE IF | DURATION | REFERENCES | REMARKS |
|--|-------------------------------|-----------------------|------------------|--|---------|
| PROCEDURES | | ALLERGY | | | |
| ^B Reposition of iris | Subconjunctiva Gentamicin | None | At completion of | Chang, et al. (2012). Clinical & experimental ophthalmology, | |
| | | | surgery | 40(7), 669-674. | |
| ^B Toilet and suturing of lids | Ointment <i>Maxitrol</i> ® | None | At completion of | Mindel J, Starr MB, Lally JM Surv | |
| (T&S) | (neomycin and polymyxin B | | surgery | Ophthalmol. 1995 May 1;39(6):485–501. | |
| | sulfates and dexamethasone) | | | 2,00 (0,1100 002. | |
| ^B Toilet and suturing of | Intravenous Ciprofloxacin 400 | None | On admission | | |
| cornea / scleral laceration | mg bd/ | | | | |
| wound | Topical Chloramphenicol | | | | |
| [¥] Evisceration | Ointment <i>Maxitrol</i> ® | None | At completion of | | |
| | (neomycin and polymyxin B | | surgery | | |
| | sulfates and dexamethasone) | | | | |
| ^B Dacrocystorhinostomy/ | Ointment <i>Maxitrol</i> ® | None | At completion of | Dulku, S., Akinmade, A., & Durrani, | |
| canaliculo- | (neomycin and polymyxin B | | surgery | O. M. (2012)Orbit, 31(1), 44-47. | |
| dacryocstorhinostomy (cdcr) | sulfates and dexamethasone) | | | | |

 $^{^{\}beta}$ = contaminated procedure

| ENT PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|---|---|---|--|---|---|
| Septoplasty | Antibiotic not recommended | Antibiotic not recommended | NA | Ottoline et al. 2013. Antibiotic Prophylaxis in Otolaryngologic Surgery. Int. Arch. Otorhinolaryngol. 17(1):85-91. | |
| Septorhinoplasty | IV Cefazolin 2g + IV Metronidazole 500mg Or IV Ampicillin/Sulbactam 3g Or | IV Cefuroxime 750mg -1.5g + IV Metronidazole 500mg Or IV Clindamycin 900mg | Intraop: 1 dose q4hrly [NA for metronidazole & Clindamycin] | Ottoline ACX et al. 2013 Int. Arch. Otorhinolaryngol. 17(1); 85-91 National Antibiotic Guideline. 2014. 2 nd Ed. Scottish Intercollegiate Guidelines Network. Antibiotic prophylaxis in surgery. 2014. 2 nd Ed www.sign.ac.uk/pdf/sign104.pdf | |
| Nasal bone reduction | IV Co-AmoxiClav 1.2g Antibiotic not recommended | Antibiotic not recommended | NA | South Australian expert Advisory Group on Antibiotic Resistance (SAAGAR) March 2012 | |
| Turbinoplasty / turbinectomy | Antibiotic not recommended | Antibiotic not recommended | NA | Scottish Intercollegiate Guidelines Network. 2014. 2 nd Ed | |
| Endoscopic surgery (including functional endoscopic sinus surgery, middle meatalantrostomy, sphenoidotomy, ethmoidectomy, endoscopic frontal surgeries,) | Antibiotic not recommended | Antibiotic not recommended | NA | National Antibiotic Guideline. 2014. 2 nd Ed. Scottish Intercollegiate Guidelines Network. 2014. 2 nd Ed | **For tumour surgery prophylaxis antibiotic is needed |

| ENT PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|---|--|---|--|---|---|
| Endoscopic CSF leak repair | IV Cefazolin 2g or IV Cefuroxime 1.5g + IV Metronidazole 500mg | IV Clindamycin 900mg | 8 hourly for further 3 doses | National Antibiotic Guideline. 2014. 2 nd Ed. | *refer neurosurgical guideline |
| Endoscopic dacrocystorhinostomy (with stenting) | IV Co-AmoxiClav 1.2g Or IV Ampicillin/Sulbactam 3g Or IV Cefazolin 2g + IV Metronidazole 500mg | IV Cefuroxime 750mg -1.5g + IV Metronidazole 500mg OR IV Clindamycin 900mg | Intraop: Repeat doseq4hrly [NA for metronidazole & Clindamycin] | National Antibiotic Guideline. 2014. 2 nd Ed Ottoline ACX et al. 2013 <i>Int. Arch. Otorhinolaryngol.</i> 17(1); 85-91 | ** if stenting done need antibiotic prophylaxis, If no stenting done, antibiotic prophylaxis is not recommended |
| Endoscopic sphenopalatine artery ligation | Antibiotic not recommended | Antibiotic not recommended | NA | Ottoline ACX et al. 2013. Int. Arch. Otorhinolaryngol. 17(1); 85- 91 | |
| Endoscopic nasopharyngectomy | IV Co-AmoxiClav 1.2g Or IV Ampicillin/Sulbactam 3g Or IV Cefazolin 2g + IV Metronidazole 500mg | IV Cefuroxime 750mg -1.5g + IV Metronidazole 500mg OR IV Clindamycin 900mg | Intraop: Repeat dose q4hrly [NA for metronidazole & Clindamycin] | National Antibiotic Guideline. 2014. 2 nd Ed. | |
| Endoscopic medial maxillectomy | IV Co-AmoxiClav 1.2g Or IV Ampicillin/Sulbactam 3g Or IV Cefazolin 2g + IV Metronidazole 500mg | IV Cefuroxime 750mg -1.5 + IV Metronidazole 500mg OR IV Clindamycin 900mg | Intraop: Repeat dose q4hrly [NA for metronidazole & Clindamycin] | National Antibiotic Guideline. 2014. 2 nd Ed. | |

| ENT PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|--|--|---|--|---|-------------------------------------|
| Transphenoidal hypophysectomy | IV Cefazolin 2g or IV Cefuroxime 1.5g + IV Metronidazole 500mg | IV Clindamycin 900mg | Repeat dose 8 hourly for further 3 doses | Little AS, White WL. 2011 Pituitary.14(2); 99-104 Orlando R et al. 2007Surgical neurology. 68(0); 145-148 National Antibiotic Guideline. 2014. 2nd Ed. | Refer neurosurgical guideline |
| Tympanoplasty | Antibiotic not recommended | Antibiotic not recommended | NA | Ottoline ACX et al. 2013. Int. Arch. Otorhinolaryngol. 17(1); 85- 91 | |
| Mastoidectomy (including atticotomy, atticoantrostomy, Cortical mastoidectomy, Modified radical mastoidectomy, radical mastoidectomy. Combined approached tympanoplasty, Facial nerve decompression) | IV Co-AmoxiClav 1.2g Or IV Ampicillin/Sulbactam 3g Or IV Cefazolin 2g + IV Metronidazole 500mg | IV Cefuroxime 750mg -1.5g + IV Metronidazole 500mg Or IV Clindamycin 900mg | Intraop: Repeat dose q4hrly [NA for metronidazole & Clindamycin] | Ottoline ACX et al. 2013. Int. Arch. Otorhinolaryngol. 17(1); 85- 91 | |
| Translabyrinthine approach | IV Cefazolin 2g or IV Cefuroxime 1.5g | IV Clindamycin 900mg | Repeat 8 hourly for further 3 doses | National Antibiotic Guideline. 2014. 2 nd Ed. | |

| ENT PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|--|---|--|--|--|---------|
| Ossicular reconstruction*** | Antibiotic not recommended | Antibiotic not recommended | NA | Ottoline ACX et al. 2013 Int. Arch. Otorhinolaryngol. 17(1); 85- 91 | |
| *** if with prosthesis | IV Co-AmoxiClav 1.2g Or IV Ampicillin/Sulbactam 3g Or IV Cefazolin 2g + IV Metronidazole 500mg | IV Clindamycin 900mg Or IV Cefuroxime 750mg -1.5g + IV Metronidazole 500mg | Intraop: repeat dose q4hrly [NA for metronidazole & Clindamycin] | National Antibiotic Guideline. 2014. 2 nd Ed. | |
| Transtympanic tube (grommet or T-tube) | Single dose of topical antibiotic: Sofradex ear drop after grommet inserted. Sofradex = framycetin sulfate and gramicidin | Ofloxacin Otic Solution | | Scottish Intercollegiate Guidelines Network. 2014. 2 nd Ed | |
| Temporal bone resection | IV Co-AmoxiClav 1.2g Or IV Ampicillin/Sulbactam 3g Or IV Cefazolin 2g + IV Metronidazole 500mg | IV Clindamycin 900mg Or IV Cefuroxime 750mg -1.5g + IV Metronidazole 500mg | Intraop: Repeat dose q4hrly [NA for metronidazole & Clindamycin] | National Antibiotic Guideline. 2014. 2 nd Ed Ottoline ACX et al. 2013. <i>nt. Arch. Otorhinolaryngol.</i> 17(1); 85-91 | |

| ENT PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF | DURATION | REFERENCES | REMARKS |
|---------------------------|---|---|---|---|---------|
| | | ALLERGY | | | |
| Stapedotomy | IV Co-AmoxiClav 1.2g Or | IV Clindamycin 900mg | Intraop: Repeat dose q4hrly [NA for | Obeso S et al. 2009 ActaOtorinolaringol Esp. 61(1): 54-68 | |
| | IV Ampicillin/Sulbactam 3g Or | IV Cefuroxime 750mg -1.5g + IV Metronidazole 500mg | metronidazole & Clindamycin] | Ottoline ACX et al. 2013. <i>Int.</i> Arch. Otorhinolaryngol. 17(1); 85- 91 | |
| | IV Cefazolin 2g + IV Metronidazole 500mg | TV Wettomaazore Sooning | | | |
| Cochlear implant | To consult specialist | | | Anne S et al. 2016 Annals of Otology, Rhinology & Laryngology. 1-7 | |
| | IV Co-AmoxiClav 1.2g | IV Clindamycin 900mg | Intraop: | National Antibiotic Guideline. | |
| Bone anchored hearing aid | Or | Or | Repeat dose q4hrly | 2014. 2 nd Ed | |
| | IV Ampicillin/Sulbactam 3g | | [NA for | | |
| | Or | IV Cefuroxime 750mg -1.5g | metronidazole & | | |
| | | + IV Metronidazole 500mg | Clindamycin] | | |
| | IV Cefazolin 2g + | | | | |
| | IV Metronidazole 500mg | | | | |
| | Antibiotic not recommended | Antibiotic not | | | |
| Canalplasty | | recommended | | | |
| | Antibiotic not recommended | Antibiotic not | | | |
| Meatoplasty | | recommended | | | |

| ENT PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF | DURATION | REFERENCES | REMARKS |
|--|--|--|---|--|---|
| Head and Neck (Clean procedure/ benign) Head and Neck 1. Clean/ clean contaminated | Antibiotic not recommended IV Co-AmoxiClav 1.2gm OR | ALLERGY Antibiotic not recommended IV Clindamycin 900mg | 1 dose prior to skin incision | National Antibiotic Guideline. 2014. 2nd Ed. Scottish Intercollegiate Guidelines Network. 2014. 2nd Ed Strauss M et al. 1997. J Laryngol Otol.; 111:631–4. | Antibiotic is NOT recommended unless implant is used. |
| for cancer surgery including procedure requiring incision through oral or pharyngeal mucosa ± neck dissection ± microvascular flap/ pedicle myocutaneous flap | IV Ampicillin + Sulbactam 3g OR IV Cefazolin 2gm + IV Metronidazole 500mg (Cefazolin 3gm for patient >120kg) | | Intraop: repeat dose q4hrly [NA for metronidazole & Clindamycin] Post Op: variable period according to the details of the individual case. | Skitarelić N et al. 2007. <i>J</i> Craniomaxillofac Surg.; 35:15–20. Johnson JTet al. 1997 Head Neck.; 19:367–71. Man LX et al. 2011 European Archives of Oto-Rhino-Laryngology 273.9: 2805-2811. Scotton W et al. 2012. European Archives of Oto-Rhino-Laryngology.; 269:2415-22. Skitarelić N et al. 2007 <i>J</i> | |
| Laryngectomy (Partial/ Total ± neck dissection) Maxillectomy (Total/ Partial/ Subtotal) Tracheal resection and anastomosis/ Cricotracheal reconstruction | | | | Craniomaxillofac Surg.; 35:15–20. Scottish Intercollegiate Guidelines Network. 2014. 2nd Ed Bratzler et al. 2013. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health- Syst Pharm.2013;70:195-283. Ottoline ACX et al. 2013 Int. Arch. Otorhinolaryngol. 17(1); 85-91 | |

| ENT PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|---|---|----------------------------|-------------------------------|--|--|
| Head and Neck (Clean cancer surgery involving neck dissection only) | IV Co-AmoxiClav 1.2gm OR IV Ampicillin + sulbactam 3g OR IV Cefazolin 2gm + IV Metronidazole 500mg (Cefazolin 3gm for patient >120kg) | Clindamycin 900mg | 1 dose prior to skin incision | Man et al. 2011 Antibiotic Prophylaxis in Uncontaminated Neck Dissection. Laryngoscope, 121:1473–1477 Bratzler et al. 2013. Am J Health- Syst Pharm. 2013;70:195-283. | Only 3 doses |
| Thyroplasty (medialization thyroplasty with implant) [clean surgery with implant] | IV Co-AmoxiClav 1.2gm OR IV Cefazolin 2gm | Clindamycin 900mg | 1 dose prior to skin incision | Abraham et al. 2001. "Complications of type I Thyroplasty and Arytenoid Adduction." <i>The Laryngoscope</i> ; 111:1322-9. | The antibiotic can be continued postoperatively for a variable period according to the details of the individual case. |
| Excision of benign neck mass (except branchial fistula excision/ sistrunk) | Antibiotic not recommended | Antibiotic not recommended | NA | Scottish Intercollegiate Guidelines Network. 2014. 2 nd Ed | Consider antibiotic in benign neck mass with risk of wound contamination. |
| Parotidectomy/ Submandibulectomy | Antibiotic not recommended | Antibiotic not recommended | NA | Johnson et al. 1987. Infection following uncontaminated head and neck surgery. Archives of Otolaryngology—Head & Neck Surgery.;113:368-9. | Consider antibiotic in long surgery time or cancer of the salivary gland. |

| ENT PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF | DURATION | REFERENCES | REMARKS |
|--|----------------------------|------------------------------------|----------|--|---------|
| Thyroidectomy/ Parathyroidectomy | Antibiotic not recommended | ALLERGY Antibiotic not recommended | NA | Avenia N, Sanguinetti A, Cirocchi R, et al. Antibiotic prophylaxis in thyroid surgery: a preliminary multi- centric Italian experience. <i>Ann Surg Innov Res.</i> 2009; 3:10. | |
| Adenoidectomy/ Tonsillectomy | Antibiotic not recommended | Antibiotic not recommended | NA | Bratzler et al. 2013. Am J Health- Syst Pharm. 2013;70:195-283. Sánchez-Carrión Set al. 2006 Utility of prophylactic antibiotics in pediatric adenoidectomy. International Journal of Pediatric Otorhinolaryngology. 70:1275-81. | |
| Endolaryngeal microsurgery/ Laser surgery | Antibiotic not recommended | Antibiotic not recommended | NA | Ottoline et al. 2013 Int. Arch. Otorhinolaryngol. 17(1):85-91 | |

4. MAXILLOFACIAL PROCEDURES

| MAXILLOFACIAL PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|--|---|----------------------------|--|--|---------|
| Extraction - One Tooth (Oral Surgery Under Local Anaesthesia) | Antibiotic not recommended | Antibiotic not recommended | NA | | |
| Excision Of Mucous Extravasation Cyst | Antibiotic not recommended | Antibiotic not recommended | NA | | |
| Management Of Infected Socket | PO 500mg Amoxycillin | PO 500mg Cefuroxime | 30-45 min before incision | | |
| Surgical Extraction - Impacted , Roots , Embedded (Oral Surgery Under Local Anaesthesia) | *Antibiotic not required in good dental hygiene and healthy patient | IV Cefuroxime 1.5g | 1 dose | | |
| Biopsy - Soft Tissue or Hard Tissue Excision - Soft Tissue or Hard Tissue Toilet And Suturing - Minor or Major Wounds Trauma Dressing Of Soft Tissue Injury - Closed Reduction And Fixation Of Fractures (Maxillofacial) - Closed Reduction And Fixation Of Fractures (Dentoalveolar) - Removal Of Fixation | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g | Intra Op: Repeat dose q 3 hours (Co-AmoxiClav) | Antibiotic Prophylaxis in Oral Surgery for Prevention of Surgical Site infection. MOH 2015. 2nd Ed. | |
| Enucleation / Marsupialisation Of Cyst Removal Of Foreign Body | | | or q 4 hours (Cefuroxime) | | |

Management Of Infected Socket

- Mini Dental Implant (Ex Cost)

Haemostasis

Incision And Drainage
Autogenous Bone Grafting

Prosthetic Surgery

MAXILLOFACIAL

| Conventional Dental Implant (Ex. Implant Cost) Sinus Lift Sulcus Deepeding Alveoloplasty MAXILLOFACIAL PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|---|-------------------------|---|---|--|---|
| Endodontic Surgery - Apicectomy - Orthodontic Implant - Exposure And Gold Chain Bonding (Ex Cost Of Chain) | | | | | |
| Nasoorbital - Close - Closed Reduction & Fixation - Open - Orif Nasoethmoid - Closed Reduction & Fixation - Open - Orif Maxilla - Le Fort 111 - Orif - Circumzygomatic Suspension Removal - Removal Of Osteosynthesis Plate - Removal Silastic - Removal Of Osteosynthesis Wire Other - Removal Of Pack Imf- Intermaxillary Screws Imf Imf- Intermaxillary Arch Bars Imf | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g No antibiotic if closed reduction via nasal | Intra Op: Repeat dose q 3 hrly (Co-AmoxiClav) or q 4 hrly (Cefuroxime) | | For combined surgeries to refer other teams To review antibiotic duration for Complicated cases and surgeries >2hrs |
| Simple Treatments - Anaesthetic Injection Arthroscopy: Upper /Lower Space Diagnostic Arthrocentesis - Arthroscopy Upper or Lower Space Arthrocentesis | Antibiotic not required | Antibiotic not required | NA | Antibiotic Prophylaxis in Oral Surgery for Prevention of Surgical Site infection. MOH 2015. 2 nd Ed. | |

| MAXILLOFACIAL PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|--|-------------------------|---------------------------|--|--|---|
| Meniscus - Menisectomy - Meniscus Alloplastic Replacement - Meniscus Repair - Meniscus Re-Attachment Condyle Removal - High Condylar Shave; Cindylectomy; Condylotomy; Gap Arthroplasty; Condyle Osteotomy Prothesis - Prosthesis Glenoid Fossa; Prosthesis Condyle Head; Prosthesis Total | | | | | |
| Root Canal Treatment - Anterior & Premolar (Conservative Dentistry) | Antibiotic not required | Antibiotic not required | NA | | |
| Coronoid - Coronoidectomy Dislocation - Manipulation / Reduction - Dislocation Capsular Plication - Extra - Articular Sclerosant Injection - Eminectomy - Zygomatic Arch Down Fracture - Eminence Augmentation - Dislocation Myotomy | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g | Intra Op: Repeat dose q3 hrly(Co-AmoxiClav) or q4hrly (Cefuroxime) | Antibiotic Prophylaxis in Oral Surgery for Prevention of Surgical Site infection. MOH 2015. 2 nd Ed. | |
| Soft Tissue - Ora - Facial- Primary Closure; Flap Repair; Scar Revision Mandible – Closed or Open Reduction Of Mandibular Fracture Zygoma - Closed Reduction - Other Technoque - Gillies Approach - Open Reduction & Internal Fixation | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g | Intra Op: Repeat dose q3 hrly(Co-AmoxiClav) or q4hrly (Cefuroxime) | | Except for close reduction. *To consult specialist on duration of antibiotic |

| MAXILLOFACIAL PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|---|----------------------|---------------------------|---|--|---|
| Orbital Floor - Repair - Orbital Floor Repair Alloplast /Autogenous / Titanium Mesh Maxilla - Le Fort 1 - Orif / Close Reduction Craniofacial - Open - Orbital Ridge Fracture Repair - Craniotomy Complicating Fracture Repair - Anterior Craniotomy Repair Excision Of Tumour And Reconstrution | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g | Intra Op: Repeat dose q3 hrly(Co-AmoxiClav) or q4hrly (Cefuroxime) | | Except for close reduction. |
| Cuteneuos - Excosion & Primary Closure - Excosion & Split Skin Graft - Excosion & Wolfe Graft - Excosion & Flap Cosure - Crysurgery - Excisional Biopsy Tumour Debulking Intraoral Soft Tissue - Eua + Biopsy Intraoral Resection - Excision Of Tumour (Unspec) / Palate / - Biopsy Tongue / Floor Of Mouth/ Partial or Total Glossectomy / Destruction Of Lesion Fom Laser Excision Bone Mandible - Mandibulotomy / Mandibular Rim Resection / Segmental Mandibulectomy/ Hemimandibulectomy / Subtotal or Total Mandibulectomy / Bone Biopsy Mandible Bone Maxillary - Hemimaxillectomy / Partial Maxillectomy / Orbital Exenteration / Bone Biopsy | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g | Intra Op: Repeat dose q3 hrly(Co-AmoxiClav) or q4hrly (Cefuroxime) | Antibiotic Prophylaxis in Oral Surgery for Prevention of Surgical Site infection. MOH 2015. 2 nd Ed. | *To consult specialist on duration of antibiotic |

| MAXILLOFACIAL PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|---|----------------------------|-------------------------------|---|--|---------|
| Parotid - Superficial Parotidectomy / Parotid Biopsy (Open) / Total Conservative Parotidectomy/ Total Radical Parotidectomy / Nerve Reconstruction In Parotidectomy Submandibular - Submandibular Gland Excision Duct - Repositioning Of Parotid Duct / Submandibular Duct Sublingual - Excision Of Sublingual Gland Minor Gland - Excision Of Minor Salivary Tumour Giant Cell - Excision Of Giant Cell Lesion Fibro - Osseous - Excision Of Fibro - Osseous Lesion Ameloblastoma - Excision | | | | | |
| E. Orthognathic Surgery (Per Jaw) | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g | Intra Op: Repeat dose q3 hrly(Co-AmoxiClav) or q4hrly (Cefuroxime) | Antibiotic Prophylaxis in Oral Surgery for Prevention of Surgical Site infection. MOH 2015. 2 nd Ed. | |
| Third Molars - Simple Extraction / Elevation Of 18, 28 / Surgical Removal Of 38, 48 / Transplantation / Multiple Surgical Removal Other Teeth - Simple Extraction / - Surgical Removal Of Retain Root/ Transplantation / Exposure/ Full Clearance Apicectomy - Apicectomy / Apicectomy + Retrograde Root Filling / Apicectomy + Cyst / Granuloma Enucleation / Root Canal Therapy | Antibiotic not recommended | Antibiotic not recommended | NA | | |

| MAXILLOFACIAL PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|--|----------------------------|----------------------------|---|---|---------|
| Cyst - Enucleation Cyst / Marsupialisation Of Cyst | | | | | |
| Fixed Appliance Removable Appliance (Orthodontics) | Antibiotic not recommended | Antibiotic not recommended | | | |
| Salivary (Minor) - Excision Of Mucocele / Biopsy Antrum - Caldwell Luc / Antrostomy / Removal Of Tooth Washout / Irrigation And Drainage Periodontal - Gingivectomy / Repositioned Flap/ Gingivoplasty / Muscosal Graft/ Bone Regeneration Techniques Soft Tissue - Frenectomy Sequestrectomy - Bone Sequestrectomy Implantology - Implan Intraoral or Extraoral Osseous Integrated . 1st Stage or 2 nd stage | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g | Intra Op: Repeat dose q3 hrly(Co-AmoxiClav) or q4hrly (Cefuroxime) | Antibiotic Prophylaxis in Oral Surgery for Prevention of Surgical Site infection. MOH 2015. 2 nd Ed. | |
| Scaling And Polishing (Periodontics) Root Debridement (Periodontics) | Antibiotic not recommended | Antibiotic not recommended | NA | | |
| Periodontal Surgery (Oral Surgery Under Local Anaesthesia) | Antibiotic not recommended | Antibiotic not recommended | NA | | |
| Abscess Drainage - Incision & Drainage I/O or E/O / Exploration Of Tissue Spaces & Drainage / | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g | 1 dose | Antibiotic Prophylaxis in Oral Surgery for Prevention of Surgical Site infection. MOH 2015. 2 nd Ed. | |
| Comprehensive - Dental Care | Antibiotic not recommended | Antibiotic not recommended | NA | | |
| Zygoma - Other - Open Reduction Zygoma (Other Technique) Prosthesis - Prosthesis Glenoid Fossa / Prosthesis Condyle Head | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g | Intra Op: Repeat dose q3 hrly(Co-AmoxiClav) or q4hrly (Cefuroxime)) | | |

| MAXILLOFACIAL PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|---|----------------------------|----------------------------|---|--|---------------------|
| Other Teeth - Surgical Removal Canine | Antibiotic not recommended | Antibiotic not recommended | NA | | |
| Antrum - Oroantral Fisula Repair Palatal Flap Antrum - Oroantral Fisula Repair Buccal Flap | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g | Intra Op: Repeat dose q3 hrly(Co-AmoxiClav) or q4hrly (Cefuroxime) | | |
| Extraction - 5-10 Tooth Extraction - 11-20 Tooth Extraction - > 20 Tooth | Antibiotic not recommended | Antibiotic not recommended | NA | Antibiotic Prophylaxis in Oral Surgery for Prevention of Surgical | |
| Remove Arch Bar | Antibiotic not recommended | Antibiotic not recommended | NA | Site infection. MOH 2015. 2 nd Ed. | |
| Distraction Osteogenesis | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g | Intra Op: Repeat dose q3 hrly(Co-AmoxiClav) or q4hrly (Cefuroxime) | | As per orthognathic |

5. BREAST & ENDOCRINE PROCEDURES

BREAST & ENDOCRINE

| BREAST & ENDOCRINE PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|--|----------------------------|-----------------------------------|---------------------------------|--|---|
| Excision Of Branchial Fistula | Antibiotic not recommended | NA | NA | Guideline for Surgical | |
| Excision Of Breast Lump | Antibiotic not recommended | NA | NA | Prophylaxis within Breast Surgery for Adult Patients. | |
| Excision Of Breast | IV Cefuroxime 1.5G | IV Erythromycin | 1 dose pre op | Nottingham University | Spillage of |
| Tumour,Microdochectomy | | 500mg over 1hr | | Hospitals antibiotic guidelines | intraductal fluid |
| Excision Of Thyroglossal Cyst | Antibiotic not recommended | NA | NA | committee. https://www.nuh.nhs.uk/hand | |
| Excision Of Retroperitonel Tumours | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5G | Intra Op: repeat dose q4hrly | lers/downloads.ashx?id=6100 3. Accessed 22 June 2017 | |
| Lymph Node Biopsy | Antibiotic not recommended | NA | NA , | | |
| Mastectomy | Antibiotic not recommended | NA | NA | Bağhaki et al. 2014. Guideline for Antimicrobial Prophylaxis in Breast Surgery. J Breast | Unless the patient had neoadjuvant chemotherapy |
| Thyroidectomy-Lobectomy | Antibiotic not recommended | NA | NA | Health; 10: 79-82 | |
| Thyroidectomy-Total & Subtotal | Antibiotic not recommended | NA | NA | | |
| Regional Lymph Nodes Excision | Antibiotic not recommended | NA | NA | | |
| Reconstruction Of Breast Using | IV Cefuroxime 1.5G | IV Erythromycin | Intra Op: repeat | | Long surgery; 4-6 |
| Latissimus Dorsi | | 500mg over 1hr | dose q4hrly | | Hours |
| Excision Of Lesion Of Submandibular Gland | Antibiotic not recommended | NA | NA | | |
| Reduction Mammoplasty And Subcutaneous Mammectomy | Antibiotic not recommended | NA | Intra Op: repeat dose q4hrly | | Long surgery; 3-4 Hours |
| Mastopexy | Antibiotic not recommended | NA | NA | | |
| Plastic & Reconstructive : Reconstruction Of Breast Using Local Flap | Antibiotic not recommended | NA | NA | | Long surgery; 6-8 Hours |
| Plastic & Reconstructive : Reconstruction Of Breast Using Tram Flap | IV Cefuroxime 1.5G | IV Erythromycin 500mg over 1hr | Intra Op: repeat dose q4hrly | | Long surgery; 6-8 Hours |

| BREAST & ENDOCRINE PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|--|----------------------------|---|---------------------------------|------------|----------------------------------|
| Plastic & Reconstructive : Removal Of Prosthesis From Breast | Antibiotic not recommended | NA | NA | | |
| Insertion Of Prosthesis Following Mastectomy | IV Co-AmoxiClav 1.2g | IV Erythromycin 500mg over 1hr | Intra Op: repeat dose q4hrly | | |
| Liposuction (Suction Assisted Lipectomy) - Breast | Antibiotic not recommended | NA | NA | | |
| Mammoplasty - Augmentation (Without Cost Of Prothesis)- Surgeri Plastic | Antibiotic not recommended | NA | NA | | |
| Mammoplasty - Reduction (Surgeri Plastic) | Antibiotic not recommended | NA | NA | | |
| Diagnostic Procedures On Skin And Subcutaneous Tissue | Antibiotic not recommended | NA | NA | | |
| Excision Or Destruction Of Lesion Or Tissue Of Skin And Subcutaneous (Up To 3) | Antibiotic not recommended | NA | NA | | |
| Excision Of Biopsy Lymph Node | Antibiotic not recommended | NA | NA | | |
| Open Hemithyroidectomy | Antibiotic not recommended | NA | NA | | |
| Thyroidectomy : Open Total/Subtotal or Endoscopic | Antibiotic not recommended | NA | NA | | |
| Neck Dissection / Re-Do Neck Dissection | Antibiotic not recommended | NA | NA | | |
| Parathyroidectomy or Re-Do Parathyroidectomy or Total Parathyroidectomy | Antibiotic not recommended | NA | NA | | |
| Sistrunk Procedure | Antibiotic not recommended | NA | NA | | Unless infected cases or fistula |
| Branchial Cyst or Fistula Excision | Antibiotic not recommended | NA | NA | | Unless infected or fistula |
| Open Adrenalectomy | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5G or IV Erythromycin 500mg over 1hr | 1 dose pre op | | |

| BREAST & ENDOCRINE P PROCEDURES | REFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|--|----------------------------|--|---------------|------------|---|
| Laparoscopic Adrenalectomy | Antibiotic not recommended | IV Cefuroxime 1.5G or IV Erythromycin 500mg over 1hr | 1 dose pre op | | Consider antibiotic in patient with Cushing syndrome because of high cortisol |
| Head And Neck : Insertion Of Chemoport | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5G or IV Erythromycin 500mg over 1hr | 1 dose pre op | | |
| Open Pancreatic Nodule Enucleation | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5G or IV Erythromycin 500mg over 1hr | 1 dose pre op | | |
| - Laparascopic Approach | Antibiotic not recommended | NA | NA | | |
| Reconstruction: Free Flaps | Antibiotic not recommended | NA | NA | | |
| Axillary Dissection/Clearance (Ad/Ac) | Antibiotic not recommended | NA | NA | | Unless the patient had neoadjuvant chemotherapy |
| Breast Augmentation – Bilateral or Unilateral | IV Cefuroxime 1.5G | IV Cefuroxime 1.5G or IV Erythromycin 500mg over 1hr | 1 dose pre op | | |
| Breast Lift (Mastopexy) – Bilateral or Unilateral | Antibiotic not recommended | NA | NA | | |
| Breast Reduction- Bilateral or Unilatera | Antibiotic not recommended | NA | NA | | Long surgery; 3-4 Hours |
| CAPSULECTOMY Or CAPSULOTOMY | Antibiotic not recommended | NA | NA | | IV Cefuroxime x 1 dose If implant present in situ |
| Change Of Implant | IV Cefuroxime 1.5G | IV Erythromycin 500mg over 1hr | 1 dose pre op | | To consult specialist for duration |

| BREAST & ENDOCRINE PR PROCEDURES | EFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|--|----------------------------|-----------------------------------|---------------|------------|---|
| Completion Ad/Ac | Antibiotic not recommended | NA | NA | | To consult specialist if patient is immuno- compromised |
| Excision Of A Breast Lump (S) / Cutaneous Lesions(S)/ Lymph Node (S)/ Accessory Breast / Bilateral Accessory Breasts | Antibiotic not recommended | NA | NA | | |
| Haematoma Evacuation | IV Cefuroxime 1.5G | IV Erythromycin 500mg over 1hr | 1 dose pre op | | To consult specialist on duration |
| Hookwire Localization & Wide Excision | IV Cefuroxime 1.5G | IV Erythromycin 500mg over 1hr | 1 dose pre op | | |
| Implant Reconstruction | IV Cefuroxime 1.5G | IV Erythromycin 500mg over 1hr | 1 dose pre op | | To consult specialist on duration |
| Insertion Of Chemoport | IV Cefuroxime 1.5G | IV Erythromycin 500mg over 1hr | 1 dose pre op | | |
| Ld or Tram Breast Reconstruction | IV Cefuroxime 1.5G | IV Erythromycin 500mg over 1hr | 1 dose pre op | | |
| Local Flap Breast Reconstruction, or Local Flap Wound Closure | Antibiotic not recommended | NA | NA | | |
| Macrodochectomy (Total Duct Excision) | IV Cefuroxime 1.5G | IV Erythromycin 500mg over 1hr | 1 dose pre op | | Intraductal fluid spillage |
| Mastectomy (Simple/Toilet) / Skin Sparing / Subcutaneous | Antibiotic not recommended | NA | NA | | Unless the patient had neoadjuvant chemotherapy |
| Mastectomy/Ssm/Scm, Ld & Implant Breast Reconstruction | IV Cefuroxime 1.5G | IV Erythromycin 500mg over 1hr | 1 dose pre op | | |
| Mastectomy/Ssm/Scm, Ad & Implant Breast Reconstruction | IV Cefuroxime 1.5G | IV Erythromycin 500mg over 1hr | 1 dose pre op | | |
| Mastectomy/Ssm/Scm, Ad & Ld / Tram Breast Reconstruction | IV Cefuroxime 1.5G | IV Erythromycin 500mg over 1hr | 1 dose pre op | | |
| Microdochectomy | IV Cefuroxime 1.5G | IV Erythromycin 500mg over 1hr | 1 dose pre op | | Intraductal fluid spillage |

| BREAST & ENDOCRINE PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|---|---|-----------------------------------|---------------|------------|---|
| Nipple Areolar Reconstruction / Tattooing/ Eversion or Nipple Reconstruction - Bilateral or Unilatera | Antibiotic not recommended | NA | NA | | |
| Punch Biopsy | Antibiotic not recommended | NA | NA | | |
| Reexcision Of A Margin (S) | IV Cefuroxime 1.5G | IV Erythromycin 500mg over 1hr | 1 dose pre op | | cavity seroma |
| Removal Of Chemoport or Implant or Suture(s) (Ros) | Antibiotic not recommended | NA | NA | | |
| Repositioning Of Implant | IV Cefuroxime 1.5G or IV Co-AmoxiClav 1.2g | IV Erythromycin 500mg over 1hr | 1 dose pre op | | |
| Scar Revision | Antibiotic not recommended | NA | NA | | |
| Sentinel Lymph Node Biopsy (Slnb) | Antibiotic not recommended | NA | NA | | |
| Skin Graft ; Full or Partial Thickness | Antibiotic not recommended | NA | NA | | |
| Skin Sparing Mastectomy (Ssm) | Antibiotic not recommended | NA | NA | | Unless the patient had neoadjuvant chemotherapy |
| Skin/Wound Debridement | Antibiotic not recommended | NA | NA | | |
| Subcutaneous Mastectomy (Scm) | Antibiotic not recommended | NA | NA | | Unless the patient had neoadjuvant chemotherapy |
| Therapeutic Mammoplasty or Therapeutic Mammoplasty + Snb | Antibiotic not recommended | NA | NA | | Unless the patient had neoadjuvant chemotherapy |
| Wedge Biopsy | Antibiotic not recommended | NA | NA | | |
| Wide Local Excisions(Wle) | Antibiotic not recommended | NA | NA | | |
| Wle & Ad/Ac or Wle & Sinb | Antibiotic not recommended | NA | NA | | Unless the patient had neoadjuvant chemotherapy |
| Wle & Ad/Ac & Implant Breast Reconstruction or Wle & Ad/Ac & Ld Breast Reconstruction | IV Cefuroxime 1.5g | IV Erythromycin 500mg over 1hr | 1 dose pre op | | |

CARDIOTHORACIC

6. CARDIOTHORACIC PROCEDURES

| CARDIOTHORACIC | PREFERRED FIRST LINE | ALTERNATIVE IF | DURATION | REFERENCES | REMARKS |
|--------------------------------|---------------------------------|----------------------------------|---------------|---|--------------------------------------|
| PROCEDURES | | ALLERGY | | | |
| Coronary artery bypass, | IV Cefazolin 2g, repeat after 4 | Vancomycin 1g or 15mg/kg | 48 hours | National Heart Institute Antibiotic | In any |
| Ventricular assist devices. | hours if procedure is >4 hours, | IV in 200mL over 2 hr | | Guideline 2014 | circumstances |
| ventriculai assist devices. | followed by 2g 8hourly post- | | | National Antibiotic Guideline. 2014. | alternative should only be used with |
| | operatively | For patients colonized with MRSA | | 2 nd Ed. | justification and |
| | PLUS IV Gentamicin 2mg/kg | WITH IVIKSA | | Ann Thorax Surg 2006;81:397–404 | verified with |
| | | Vancomycin 1g or 15mg/kg | | | specialist and consultant. |
| | or | IV in 200mL over 2 hrs. | | Ann Thorac Surg 2007;83:1569–76 | consultant. |
| | IV Cefuroxime 1.5g q4H | | | UMMC Antibiotic Guideline 2014 | |
| | intraoperatively followed by | PLUS Cefazolin 2g | | Sousa-Uva M et al. 2017 | |
| | q8hrly post operatively | | | European Journal of Cardio-Thoracic Surgery: 1–29 | |
| | or | | | Surgery. I 23 | |
| | | | | | |
| | IV Cloxacillin + IV gentamicin | | | | |
| Implantation of cardiac device | IV Cefazolin 2g | | 1 dose pre op | Baddour et al 2010. Update on | |
| (pacemaker, ICD, CRTD) | | | | cardiovascular implantable electronic device infections and their | |
| (by cardiologist) | | | | management: a scientific statement from the American Heart Association. | |
| (by cardiologist) | | | | Circulation. 121(3):458. | |
| | | | | | |
| Non cardiac procedures(| IV Cefazolin 2g, repeat after 4 | | 48hours | | |
| including lobectomy, | hours if procedure is >4 hours, | | | | |
| pneumonectomy, lung | followed by 2g 8hourly post- | | | National Heart Institute Antibiotic | |
| resection, and thoracotomy), | operatively | | | Guideline 2014 | |
| Video-assisted thoracoscopic | | | | | |
| surgery | | | | | |

7. VASCULAR PROCEDURES

VASCULAR

| VASCULAR PROCEDURES | PREFERRED FIRST LINE* | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|---|----------------------------|--|---------------|---|---|
| HSV ligation, Stripping and multiple stab avulsion. (Superficial venous surgery.) | Antibiotic not recommended | Antibiotic not recommended | 1 dose pre op | National Antibiotic Guideline. 2014. 2 nd Ed. Use iv antibiotic if presence of venous ulcer | IV Co-AmoxiClav 1.2g if there is active ulcer |
| Carotid endareterectomy | IV Co-AmoxiClav 1.2g | IV Cefazolin 2g MRSA Colonized IV Vancomycin 1g or 15mg/kg in 200mL over 2 hr | 1 dose pre op | Bratzler DW. 2013Am J Health Syst Pharm. Feb 1;70(3):195-283 Nottingham NHS (2014) https://www.nuh.nhs.uk/handler s/downloads.ashx?id=61005 | |
| Emergency embolectomy | IV Co-AmoxiClav 1.2g | IV Cefazolin 2g | 1 dose pre op | https://www.sahealth.sa.gov.au/ wps/wcm/connect/257f0b004f91 779c91cadbc4163822ed/Vascular Oct2014. | |
| Femoral popliteal bypass/ any distal bypass | IV Co-AmoxiClav 1.2g | IV Cefazolin 2g | | | |
| AVF | Oral Cephalexin 500mg | IV Cefazolin 2g | 1 dose pre op | https://www.sahealth.sa.gov.au/ wps/wcm/connect/257f0b004f91 779c91cadbc4163822ed/Vascular Oct2014. Surgical Antibiotic Prophylaxis Guideline – Vascular Surgery (Government of South Australia) http://www.albertahealthservice s.ca/assets/Infofor/hp/if-hp- antimicrobial-stewardship- surgical-prophylaxis.pdf | |

| VASCULAR PROCEDURES | PREFERRED FIRST LINE* | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|---|-----------------------|--|---|--|---|
| Abdominal aortic aneurysm (AAA) excision and onlay graft | IV Co-AmoxiClav 1.2g | IV Cefazolin 2g | 1 dose pre op IntraOp: repeat dose q4hrly | | |
| Aorto-bifemoral/ aorto-iiliac | IV Co-AmoxiClav 1.2g | | 1 dose pre op | | |
| Aorto –open op of renal/visceral branch | IV Co-AmoxiClav 1.2g | | 1 dose pre op | | |
| Arteriovenous malformation(AVM) | IV Co-AmoxiClav 1.2g | | 1 dose pre op | | |
| Bypass with wound | IV Co-AmoxiClav 1.2g* | IV Cefazolin 2g MRSA Colonized IV Vancomycin 1g or 15mg/kg in 200mL over 2 hrs. | | If a non infected wound* culture is known. Use the most appropriate broad spectrum antibiotic to cover for the organism. If MRSA is isolated or suspected. Consider vancomycin. | Serve Vancomycin for patient with known/suspected MRSA colonizer. |
| Deep Venous Surgery | IV Co-AmoxiClav 1.2g | | 1 dose pre op | | |
| Vascular graft implants a. AVF graft b. Aortic graft / TEVAR / EVAR | IV Co-AmoxiClav 1.2g | MRSA infection prophylaxis IV Vancomycin 1g or 15mg/kg in 200mL over 2 hrs. | 1 dose pre op | National Antibiotic Guideline. 2014. 2 nd Ed. | |

^{*} if there is a recent positive culture prior to surgery in a non-infected wound, to revise antibiotic prophylaxis according to culture result.

8. UPPER GI & BARIATRIC PROCEDURES

UPPER GI & BARIATRIC

| UPPER GI & BARIATRIC PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|---------------------------------|----------------------|--------------------------|----------------------|--------------------------------|---------------------|
| Fundoplication (Nissen) | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g | At induction of | National Antibiotic Guideline. | If allergic to beta |
| Laparoscopic | | | anaesthesia | 2014. 2 nd Ed. | lactamase, to use |
| Gastroduodenoscopy | Not required | Not required | Not required | | clindamycin (for |
| Gastroscopy | Not required | Not required | Not required | | all procedures) |
| Gastrostomy/Jejunostomy | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g | At induction of | | |
| | | | anaesthesia | | |
| Hellers Operation Laparoscopic | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g | At induction of | | |
| | | | anaesthesia | | |
| Herniorrhaphy | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g | At induction of | | |
| | | | anaesthesia | | |
| Repair Of Umbilical Hernia | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g | At induction of | | |
| | | | anaesthesia | | |
| Small Bowel Resection, | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g + | At induction of | | |
| Ileocolectomy,Ileocolostomy, | | IV metronidazole 500mg | anaesthesia | | |
| Jejuno-Jejunostomy | | | | | |
| Abdomen Gastrointestinal : | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g | At induction of | | |
| Diagnostic Laparoscopy | | | anaesthesia | | |
| Gastrectomy-Partial & Total | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g | At time of induction | | |
| Oesophagectomy | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g | At induction of | | |
| | | | anaesthesia | | |
| OESOPHAGOGASTRECTOMY | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g + | At induction of | + | |
| With Colon Interposition | | IV metronidazole 500mg | anaesthesia | | |
| Oesophagogastrectomy And | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g + | At induction of | | |
| Interposition Of Viscus | | IV metronidazole 500mg | anaesthesia | | |
| Open Excision Of Lesion Of | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g + | At induction of | | |
| Oesophagus | | IV metronidazole 500mg * | anaesthesia | | |
| | | | At induction of | | |
| Bypass Of Oesophagus | IV Co-AmoxiClav 1.2g | | anaesthesia | | |

| UPPER GI & BARIATRIC | PREFERRED FIRST LINE | ALTERNATIVE IF | DURATION | REFERENCES | REMARKS |
|----------------------------------|----------------------|--------------------------|-----------------|--------------------------------|---------------------|
| PROCEDURES | | ALLERGY | | | |
| Revision Of Oesophageal | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g | At induction of | National Antibiotic Guideline. | |
| Anastomosis | | | anaesthesia | 2014. 2 nd Ed. | |
| Thoracoscopic Repair Of | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g | At induction of | | |
| Oesophagus | | | anaesthesia | | If allergic to beta |
| Thoracoscopic Oesophagectomy | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g + | At induction of | | lactamase, to use |
| And Interposition Of Viscus | | IV metronidazole 500mg * | anaesthesia | | clindamycin (for |
| | | | | | all procedures) |
| Laparoscopic Sleeve | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g | At induction of | | |
| Gastrectomy | | | anaesthesia | | |
| Laparoscopic Gastric Bypass | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g | At induction of | | |
| | | | anaesthesia | | |
| Primary Repair Of Hernia | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g | At induction of | National Antibiotic Guideline. | |
| | | | anaesthesia | 2014. 2 nd Ed. | |
| Laparoscopic Repair Of Inguinal | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g | At induction of | | |
| Hernia (Unilateral or Bilateral) | | | anaesthesia | | |
| Repair Of Recurrent Inguinal | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g | At induction of | | |
| Hernia | | | anaesthesia | | |
| Primary Repair Of Incisional | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g | At induction of | | |
| Hernia | | | anaesthesia | | |
| Repair Of Recurrent Incisional | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g | At induction of | | |
| Hernia | | | anaesthesia | | |
| Repair Of Other Hernia Of | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g | At induction of | | |
| Abdominal Wall | | | anaesthesia | | |

9. COLORECTAL PROCEDURES

COLORECTAL

| COLORECTAL PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS | | |
|---|---|---|---|---|---|---|--|
| Abdomino perineal resection | IV Co-AmoxiClav 1.2g Or IV Cefazolin 2g + IV Metronidazole 500mg | IV Metronidazole 500mg | 1 dose Pre Op Intra Op: 1 dose q 4 hrs [NA for metronidazole & Gentamicin] | Bratzler DW. 2013Am J Health Syst Pharm. Feb 1;70(3):195-283 South Australian expert Advisory Group on Antibiotic Resistance (SAAGAR). 2014. | Health Syst Pharm. Feb 1;70(3):195-283 South Australian expert Advisory Group on | Health Syst Pharm. Feb 1;70(3):195-283 South Australian expert Advisory Group on | |
| Abdomen gastrointestinal : Ileostomy/colostomy | Antibiotic Not Recommended | Antibiotic not recommended | NA | (SAAGAR). 2014. Nelson RL et al. 2014. Cochrane Database Syst | | | |
| Anoplasty | IV Co-AmoxiClav 1.2g Or IV Cefazolin 2g + IV Metronidazole 500mg | IV Gentamicin 2mg/kg + IV Metronidazole 500mg | 1 dose Pre Op Intra Op: 1 dose q 4 hry [NA for metronidazole & Gentamicin] | Cochrane Database Syst Rev. (5):CD001181. Antibiotic prophylaxis guideline for colorectal, hepatobiliary and vascular surgery for adult patients https://www.nuh.nhs.uk/ha ndlers/downloads.ashx?id=6 1005 Nottingham Antibiotic Guidelines Committee 2014 | | | |
| Ano-rectal [pull through] operation | IV Co-AmoxiClav 1.2g Or IV Cefazolin 2g + IV Metronidazole 500mg | IV Gentamicin 2mg/kg + IV Metronidazole 500mg | 1 dose Pre Op Intra Op: 1 dose q 4 hrs [NA for metronidazole & Gentamicin] | | | | |
| Anterior resection with or without colostomy | IV Co-AmoxiClav 1.2g Or IV Cefazolin 2g + IV Metronidazole 500mg | IV Gentamicin 2mg/kg + IV Metronidazole 500mg | 1 dose Pre Op Intra Op: 1 dose q 4 hrs [NA for metronidazole & Gentamicin] | | | | |

COLORECTAL

| COLORECTAL PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|--|--|---------------------------|--|------------|---------|
| Closure of colostomy (ileostomy) | IV Co-AmoxiClav 1.2g Or | IV Gentamicin 2mg/kg + | 1 dose Pre Op | See above | |
| (incostoring) | IV Cefazolin 2g + IV Metronidazole 500mg | IV Metronidazole 500mg | Intra Op: 1 dose q 4 hrs [NA for metronidazole & Gentamicin] | | |
| Colonoscopy with or without polypectomy | Antibiotic Not Recommended | NA | NA | | |
| Excision of fissure-in-ano | IV Metronidazole 500mg | - | 1 dose Pre Op | | |
| Fistulectomy | IV Metronidazole 500mg | - | 1 dose Pre Op | - | |
| Haemorrhoidectomy | IV Metronidazole 500mg | - | 1 dose Pre Op | | |
| Revision of colostomy | IV Co-AmoxiClav 1.2g Or | IV Gentamicin 2mg/kg | 1 dose Pre Op | | |
| | IV Cefazolin 2g + IV Metronidazole 500mg | IV Metronidazole 500mg | Intra Op: 1 dose q 4 hrs [NA for metronidazole & Gentamicin]] | | |
| Revision of gastrointestinal anastomosis | IV Co-AmoxiClav 1.2g Or | IV Gentamicin 2mg/kg + | 1 dose Pre Op | | |
| anastomosis | IV Cefazolin 2g + IV Metronidazole 500mg | IV Metronidazole 500mg | Intra Op: 1 dose q 4 hrs [NA for metronidazole & Gentamicin] | | |
| Sigmoidectomy | IV Co-AmoxiClav 1.2g Or | IV Gentamicin 2mg/kg | 1 dose Pre Op | | |
| | IV Cefazolin 2g + IV Metronidazole 500mg | IV Metronidazole 500mg | Intra Op: 1 dose q 4 hrs [NA for metronidazole & Gentamicin] | | |

COLORECTAL

| COLORECTAL PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|---|----------------------------|---------------------------|---|------------|---------|
| Small bowel resection, | IV Co-AmoxiClav 1.2g | IV Gentamicin 2mg/kg | 1 dose Pre Op | | |
| ileocolectomy,ileocolostomy, | Or | + | | | |
| jejuno-jejunostomy | | IV Metronidazole 500mg | Intra Op: 1 dose q 4 hrs | | |
| | IV Cefazolin 2g + | | [NA for metronidazole & | | |
| | IV Metronidazole 500mg | | Gentamicin] | | |
| Total colectomy, | IV Co-AmoxiClav 1.2g | IV Gentamicin 2mg/kg | 1 dose Pre Op | | |
| hemicolectomy | Or | + | | | |
| | N/ Coforalia 2a . | IV Metronidazole 500mg | Intra Op: 1 dose q 4 hrs [NA for metronidazole & | See above | |
| | IV Cefazolin 2g + | | | | |
| | IV Metronidazole 500mg | | Gentamicin] | | |
| Stapled haemorrhoidopexy | IV Metronidazole 500mg | - | 1 dose Pre Op | | |
| Starr procedure | IV Metronidazole 500mg | - | 1 dose Pre Op | | |
| Laparoscopic colectomy | IV Metronidazole 500mg | - | 1 dose Pre Op | | |
| Laparoscopic anterior | IV Co-AmoxiClav 1.2g | IV Gentamicin 2mg/kg | 1 dose Pre Op | | |
| resection | Or | + | | | |
| | | IV Metronidazole 500mg | Intra Op: 1 dose q 4 hrs [| | |
| | IV Cefazolin 2g + | | NA for metronidazole & | | |
| | IV Metronidazole 500mg | | Gentamicin] | | |
| Laparoscopic APR | IV Cefazolin 2g + | IV Gentamicin 2mg/kg | 1 dose Pre Op | | |
| | IV Metronidazole 500mg | + | | | |
| | | IV Metronidazole 500mg | Intra Op: 1 dose q 4 hrs [| | |
| | | | NA for metronidazole] | | |
| Laparoscopic total colectomy | IV Co-AmoxiClav 1.2g | IV Gentamicin 2mg/kg | 1 dose Pre Op | | |
| | Or | + | | | |
| | N/ 0 f 1: 0 | IV Metronidazole 500mg | Intra Op: 1 dose q 4 hrs [| | |
| | IV Cefazolin 2g + | | NA for metronidazole & | | |
| To a constant of the constant | IV Metronidazole 500mg | | Gentamicin] | | |
| Transanal resection of rectal | IV Metronidazole 500mg | - | 1 dose Pre Op | | |
| Sigmoidoscopy | Antibiotic Not Recommended | NA | NA | | |

| HEPATOBILIARY PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|---|---|---|---|---|--|
| Open cholecystectomy+/- biliary exploration or laparoscopic cholecystectomy (high risk)+/- biliary exploration | No antibiotic [If high risk, IV Co-AmoxiClav 1.2g] | No antibiotic | NA | Antimicrobial prophylaxis for surgery. Treat guidel Med Lett 2012;10:73 Bratzler DW. 2013. Am J Health Syst Pharm. Feb 1;70(3):195-283 | High risk- factors that indicate high risk include age>70 years, pregnancy,acute cholecystitis,nonfunction ing gallbladder, obstructive jaundice, common bile duct stone, immunosuppression. |
| Laparoscopic cholecystectomy | Antibiotic Not Recommended | NA | NA | | |
| Whipples procedure/ pylorus preserving pancreaticoduodenectomy(PPPD) / distal pancreatectomy/ drainage procedure | IV Co-AmoxiClav 1.2g Or IV Cefazolin 2g + IV Metronidazole 500mg | IV Gentamicin 2mg/kg + IV Metronidazole 500mg | 1 dose Pre Op Intra Op: 1 dose q 4 hrs [NA for metronidazole] | Antimicrobial prophylaxis for surgery. Treat guidel Med Lett 2012;10:73 | |
| Hepatectomy(major/minor) | IV Co-AmoxiClav 1.2g Or IV Cefazolin 2g + IV Metronidazole 500mg | IV Gentamicin 2mg/kg + IV Metronidazole 500mg | 1 dose Pre Op Intra Op: 1 dose q 4 hrs [NA for metronidazole] | Antimicrobial prophylaxis for surgery. Treat guidel Med Lett 2012;10:73 | |

HEPATOBILIARY

| HEPATOBILIARY PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|-----------------------------|---|---|--|---|---------|
| Splenectomy | IV Co-AmoxiClav 1.2g Or IV Cefazolin 2g + IV Metronidazole 500mg | IV Gentamicin 2mg/kg + IV Metronidazole 500mg | 1 dose Pre Op Intra Op: 1 dose q 4 hrs [NA for metronidazole] | Antimicrobial prophylaxis for surgery. Treat guidel Med Lett 2012;10:73 | |
| ERCP | IV Co-AmoxiClav 1.2g Or IV Cefazolin 2g + IV Metronidazole 500mg | IV Gentamicin 2mg/kg + IV Metronidazole 500mg | 1 dose Pre Op Intra Op: 1 dose q 4 hrs [NA for metronidazole] | | |

11. UROLOGY PROCEDURES

UROLOGY surgery

| UROLOGY PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|--|---|--|---------------|---|--|
| Minor cystoscopic procedures | Antibiotics not recommended | NA | NA | EAU's Guidelines on Urological Infections. 2015. | |
| Urodynamic study | Antibiotics not recommended | NA | NA | EAU's Guidelines on Urological Infections. 2015. | |
| Transrectal biopsy of prostate | Oral Ciprofloxacin 500mg | Oral Co-AmoxiClav 625mg | 1 dose pre op | EAU's Guidelines on Urological Infections. 2015. | Control of bacteriuria prior to surgery. |
| Transurethral Resection of Bladder Tumor [TURBT] | IV Co-AmoxiClav 1.2 g | IV ciprofloxacin 400mg | 1 dose pre op | EAU's Guidelines on Urological Infections. 2015. | Control of bacteriuria prior to surgery. |
| Transurethral Resection of the Prostate [TURP] | IV Co-AmoxiClav 1.2 g + IV Gentamicin 80mg | IV ciprofloxacin 400mg + IV Gentamicin* 2mg/kg *(if renal impaired,omit /adjust gentamicin dose) | 1 dose pre op | EAU's Guidelines on Urological Infections. 2015. UMMC 2014 MyNAG 2014 NHS Nottingham 2017 | Control of bacteriuria prior to surgery. |
| Ureteroscopy [URS] / Retrograde intrarenal surgery [RIRS]/ Percutaneous NephroLithotomy [PCNL] | IV Co-AmoxiClav 1.2 g + IV Gentamicin | IV ciprofloxacin 400mg + IV Gentamicin* 2mg/kg *(if renal impaired,omit /adjust gentamicin dose) | 1 dose pre op | EAU's Guidelines on Urological Infections. 2015. NHS Nottingham 2017 | Control of bacteriuria prior to surgery. |
| Extracorporeal Shock Wave Lithotripsy [ESWL] | Antibiotics not recommended | NA | NA | EAU's Guidelines on Urological Infections. 2015. | |

| UROLOGY PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|--|-----------------------------|---|---|---|--|
| Open or laparoscopic surgery such as nephrectomy, cystectomy and prostatectomy | IV Co-AmoxiClav 1.2 g | IV ciprofloxacin 400mg or IV Gentamicin* 2mg/kg *(if renal impaired,omit /adjust gentamicin dose) | 1 dose pre op | EAU's Guidelines on Urological Infections. 2015. NHS Nottingham 2017 | |
| Scrotal surgery such as hydrocoele and vasectomy | Antibiotics not recommended | NA | NA | EAU's Guidelines on Urological Infections. 2015. | |
| Tenckhoff insertion for Peritoneal Dialysis | IV Cefazolin 1g | If colonized with MRSA IV Vancomycin 1g or 15mg/kg in 200mL over 2 hr | Immediately before tenckhoff insertion. | International Society for Peritoneal Dialysis (ISPD) 2000, 2016; ASHP Therapeutic Guidelines (2013-2017); NEPHROLOGY 2004; 9, S72–S75 The CARI Guidelines | No pre-soaking of catheter in Vancomycin |
| Permanent catheter insertion for Hemodialysis | IV Cefazolin 1g | If colonized with MRSA IV Vancomycin 1g or 15mg/kg in 200mL over 2 hr | 1 dose pre op | Guidelines for Adult Antibiotic Prophylaxis during IR Procedures Nov 2010; Uptodate 2017 | |

Obstetrics Procedures

Addendum:

- In penicillin/ cephalosporin allergy, use IV erythromycin 500mg
- If the procedure prolonged >3 hours or blood loss >1.5L, second dose of antibiotic should be administered 4 hours after the initial dose.
- In obese women >35kg/m² the antibiotic dose should be doubled

| OBSTETRICS PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|-----------------------|----------------------|----------------------------------|--|--|--|
| Caesarean section | IV Cefuroxime 1.5g | IV Ampicilin /Sulbactam 1.5gm | 1 dose prior to skin incision; For emergency cases antibiotic can be given in labour room (or before cord clamping) | National Antibiotic Guideline. 2014. 2nd Ed. UMMC Antibiotic Guideline 2014 RCOG . 2011 National Institute for Health and Clinical Excellence. CG132 Caesarean Section. Available at: http://guidance.nice.org.uk/CG 132: to avoid Co-AmoxiClav Costantine MM, Rahman M, Ghulmiyah L, Byers BD, Longo M, Wen T, et al.Timing of perioperative antibiotics for caesarean delivery: a metaanalysis. Am J Obstet Gynecol 2008;199(3):301.e1–6 Buppasiri et al. Antibiotic Guideline 2015-2016. Johns Hopkins Medicine | To add metronidazole if recurrent caesarean. |

| OBSTETRICS PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|------------------------|--|-------------------------------|---|---|--|
| Caesarean hysterectomy | IV Cefuroxime 1.5g + IV metronidazole 500 mg | IV Ampicilin/ Sulbactam 1.5gm | 1 dose pre Op IntraOp: 1 dose q 4 hours or if blood loss > 1.5L | National Antibiotic Guideline. 2014. 2nd Ed. WHO 2015. Recommendations for prevention and treatment of maternal peripartum infections. http://www.who.int/reproductive health/publications/maternal_perinatal_health/peripartum-infections-brief/en/(Accessed on 1 July 2017) ACOG 2009 Practice Bulletin, Clinical Management Guideline for Obstetricians and Gynaecologists. Number 104. Ayeleke RO 2017 Antibiotic prophylaxis for elective hysterectomy Cochrane Database Syst Rev. Jun18;6:CD004637pub2 | Mostly PPH, hence second dose should be administered 4 hours later |
| Cervical cerclage | Not indicated | NA | NA | | Mostly bacterial vaginosis has been excluded, otherwise need Metronidazole |

| OBSTETRICS PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|----------------------------|--|--|---------------|--|-----------------------------------|
| Manual removal of placenta | IV Co-Amoxiclav 1.2 gm | IV Cefuroxime 1.5 gm + IV Metronidazole 500mg Or IV Ampicilin/ Sulbactam 1.5g | 1 dose pre Op | WHO 2015. Recommendations for prevention and treatment of maternal peripartum infections. http://www.who.int/reproductive health/publications/maternal_perinatal_health/peripartum-infections-brief/en/(Accessed on 3rd_July 2017) Chong et al. 2014. Prophylactic antibiotics for manual removal of retained placenta in vaginal birth. Cochrane Database of Systematic Reviews, Issue 10. Art. No.: CD004904. Chibueze et al. 2015. Prophylactic antibiotics for manual removal of retained placenta during vaginal birth: a systematic review of observational studies and metaanalysis. BMC Pregnancy and Childbirth (15):313: | |
| Intrauterine temponade | IV Cefuroxime 750mg tds + IV Metronidazole 500mg tds | IV Co-AmoxiClav 1.2 gm Or IV Ampicilin/ Sulbactam 1.5g | | National Technical Committee Confidential Enquiries Into Maternal Deaths 2016. Quick Reference Guide Postpartum Haemorrhage (PPH) http://fh.moh.gov.my/v3/index.ph p/component/jdownloads/send/1 8-sektor-kesihatan-ibu/344-quick- reference-guide-of-postpartum- hemorrhage?option=com_jdownlo ads. Accessed 3 rd July 2017 | Usually associated with PPH |

OBSTETRIC & GYNAECOLOGY

| OBSTETRICS PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|--|------------------------|---|-------------|---|--|
| Episiotomy | Not indicated | NA | NA | | |
| Anal sphincter repair (3 rd and 4 th degree) | IV Co-AmoxiClav 1.2 gm | IV Cefuroxime 1.5g + IV metronidazole 500mg | See remarks | National Antibiotic Guideline. 2014. 2 nd Ed. Antibiotic prophylaxis for thirdand fourth-degree perineal tear during vaginal birth. Cochrane Database Syst Rev 2010;(11):CD005125 | To consult specialist on the duration. (contaminated procedures) |
| Chorionic villious sampling | Not indicated | NA | NA | | |
| Amniocentesis | Not indicated | NA | NA | | |
| Surgical TOP/ Evacuation | Not indicated | NA | NA | | |

Gynaecology procedures

Addendum:

- In penicillin/ cephalosporin allergy, use IV erythromycin 500mg
- If the procedure prolonged >3 hours or blood loss >1.5L, second dose of antibiotic should be administered 4 hours after the initial dose
- In obese women >35kg/m² the antibiotic dose should be doubled

| GYNAECOLOGY PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE | DURATION | REFERENCES | REMARKS |
|---|----------------------|--|---------------|--|-------------------------------|
| Laparotomy: Hysterectomy (simple/ radical), lymphadenectomy, omentectomy, cystectomy, oophorectomy, myomectomy, salpingectomy/ tubal ligation | IV Co-AmoviClay 1.2g | IV Cefuroxime 1.5 gm + IV Metronidazole 500mg Or IV Ampicilin/ Sulbactam | 1 dose pre op | NHS: IV Co-amoxiclav 1.2g alt Cefuroxime + metronidazole SCOG: 1 st or 2 nd Gen cephalosporin | |
| Laparoscopic: Hysterectomy (TLH/ LAVH) or when need to access uterine cavity or vagina | | 1.5g | | Chang WC, Lee MC, Yeh LS, Hung YC, Lin CC, Lin LY. Aust N Z J Obstet Gynaecol 2008;48:592–5. | |
| Laparoscopic sterilization | Not indicated | NA | NA | NA | Laparoscopic sterilization |
| | | | | | |
| | | | | | |

OBSTETRIC & GYNAECOLOGY

| GYNAECOLOGY PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE | DURATION | REFERENCES | REMARKS |
|--|------------------------|---|---------------|--|--|
| Diagnostic Laparoscopy and Dye insufflation test | Not indicated | NA | NA | | IV Co- amoxiclav 1.2g Or cefuroxime + metronidazole if Dye spillage to the intraabdominal cavity may introduce infection |
| Vaginal hysterectomy | IV Co-AmoxiClav 1.2 gm | IV Cefuroxime 1.5 gm + IV Metronidazole 500mg Or IV Ampicilin/ Sulbactam 1.5g | 1 dose pre op | Antibiotic Prophylaxis in Gynaecologic Procedures SOGC Clinical Practice Guideline No 275, April 2012 ACOG practice bulletin No. 104:.2009. Obstet Gynecol.;113(5):1180.: | |
| Colporaphy , ligament fixation | Not indicated | NA | NA | | Unless entering/ exposing the pelvic cavity |
| Ovarian cyst aspiration transvaginally | Not indicated | NA | NA | | Prophylaxis may be indicated if not previously screened for vaginal infection |

OBSTETRIC & GYNAECOLOGY

| GYNAECOLOGY PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE | DURATION | REFERENCES | REMARKS |
|--|----------------------|---|---------------|--|--|
| LEEP/LETZ | Not indicated | NA | NA | | Unless positive bacterial/ unknown BV status- need Metronidazole |
| Hysteroscopy | Not indicated | NA | NA | Kasius J, Broekmans F, Fauser B, Devroey P, Fatemi H. Fertil Steril 2011;95:792–4. | |
| Cervical/ Vagina/ Vulva biopsy | Not indicated | NA | NA | | |
| Vulvectomy (Total/ partial) radical vulvectomy | IV Co-AmoxiClav 1.2g | IV Cefuroxime 1.5g + IV Metronidazole 500mg | 1 dose pre op | | |
| Vaginectomy (Total/ partial) | IV Co-AmoxiClav1.2 g | IV Cefuroxime 1.5g + IV Metronidazole 500mg | 1 dose pre op | | |
| Inguinal lymphadenectomy | IV Co-AmoxiClav1.2 g | IV Cefuroxime 1.5g + IV Metronidazole 500mg | 1 dose pre op | | |

ORTHOPAEDIC

13. ORTHOPEDIC PROCEDURES

| ORTHOPEDIC PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|---|----------------------|---------------------------|------------------------------------|--|--|
| Diagnostic Arthroscopy & Meniscus repair | IV Cefazolin 2G | IV Clindamycin 900mg | 1 dose | PPUKM guideline National guideline 2014 | |
| Arthrsocopic ligamentous reconstruction | IV Cefazolin 2G | IV Clindamycin 900mg | 1 dose , then 3 doses post op | PPUKM guideline National guideline 2014 | |
| Joint replacements (shoulder, hip, knee, ankle) | IV Cefazolin 2g | IV Clindamycin 900mg | 1 dose, then 3 doses post op | Southwell-Keely et al. 2004. Clin Orthop Relat Res (419):179–184. www.aaos.org/about/papers/adv istmt/1027.asp (date last accessed 18 July 2017).: Berríos-Torres et al 2017. JAMA Surg. Published online May 3, 2017: JA. Bosco, MD, et a 2015. JAm Acad Orthop Surg. Aug;23(8):e27-35. PPUKM guideline 2012 Yeap et al 2006. Med J Malaysia. 61(2): 181-8 | Cefazolin (< 120kg 2g, >120kg 3g; redose q 4 hrs) [1,2] |
| Open reduction and internal fixation of long bones fractures (closed) | IV Cefuroxime 1.5G | IV Clindamycin 900mg | 1 dose, then 750MG TDS for 3 doses | Southwell-Keely et al. 2004.: a metaanalysis. Clin Orthop Relat Res (419):179–184 Bratzler et al. Am J Health Syst Pharm. 2013 Feb 1;70(3):195-283. National guideline 2014 2nd Ed Yeap et al 2006. Med J Malaysia. 61(2): 181-8 | |

ORTHOPAEDIC

| ORTHOPEDIC PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|--------------------------------------|--|---|--|---|---------|
| Open fracture | IV Co-AmoxiClav 1.2G tds | IV Cefuroxime 1.5G tds | Continue until 1st debridement | British Association of Plastic, Royal Society of Medicine Press. | |
| Open fracture (1st debridement) | IV Co-AmoxiClav 1.2G & Gentamicin 1.5mg/kg | IV Cefuroxime 1.5G & IV Gentamicin 1.5mg/kg | Given as stat dose and Co- AmoxiClav/cefuroxime continued until soft tissue closure or maximum of 72 hours | | |
| Non instrumented spinal surgery/Disc | IV Cefazolin 2g (< 120kg :2g, >120kg :3g; redose every 4 hrs) or IV Cefuroxime 1.5G | IV Clindamycin 900mg | 1 dose | Shaffer WO et al. 2013. An Evidence based clinical guidelines for multidisciplinary spine care. The Spine Jn (13) 1387-1392. Bratzler et al. 2013. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health-Syst Pharm.2013;70:195-283. UMMC 2014 National Antibiotic Guideline 2014 | |

ORTHOPAEDIC

| ORTHOPEDIC PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|-----------------------------|---|---------------------------|---|---|---------|
| Instrumented Spinal Surgery | IV Cefazolin 2g (< 120kg: 2g, >120kg: 3g; redose every 4 hrs) or IV Cefuroxime 1.5G | IV Clindamycin 900mg | Follow by 2 doses post operatively: for 2 days in high risk patients (for pts with dura leak, to consult specialist) | Berríos-Torres et al. 2017 <i>JAMA Surg.</i> : In prosthetic joint arthroplasty Takemoto et al. 2015. <i>J Bone Joint</i> Surg Am <u>97 (12) p 979-986</u> | |
| All Spinal Surgeries | Vancomycin powder 1 ampoule | - | Subcutaneous application prior to skin closure | Bakhsheshian J. 2015 World Neurosurgery. 83(5)2015, 816- 823. Kanayama et al. 2007 J Neurosurg Spine 2007;6:327–9. | |

14. PAEDIATRIC SURGERY (The list is not exhaustive)

| PAEDIATRIC SURGERY | P | REFERRED FIRST | LINE | IF MAJOR REACT | TION TO BETA- | - LACTAMS++ | DURATION | REFERENCES | REMARKS |
|---|---------------|---|----------------|------------------|--|---|----------|--|---|
| HEAD AND NECK (Clean procedure e.g. excision biopsy/benign lesion including thyroid surgery) | Antibiotic no | t recommended | | Antibiotic not r | ecommended | d | NA | National Antibiotic Guideline. 2014. 2nd Ed. Avenia N, Sanguinetti A, Cirocchi R, et al. Antibiotic prophylaxis in thyroid surgery: a preliminary multicentric Italian experience. <i>Ann Surg Innov Res.</i> 2009; 3:10. | Antibiotic is not recommended unless implant is used. Consider antibiotic in benign neck mass with risk of wound contamination |
| GASTROINTESTINAL | Cefazolin* | 30 mg/kg | Intraoperative | Clindamycin pl | us gentamici | n | | Scottish Intercollegiate | |
| Esophageal, gastroduodenal gastrostomy placement/revision/ conversion to other feeding tubes OR high- risk conditions | oesophageal | (2 gm, 3 g for pts ≥ 120 kg. gastroduodenal: r obstruction, decreased gastrointe | eased gastric | Clindamycin | 2.5 mg/kg (900 mg) 2.5 mg/kg [based on dosing weight] (5 mg/kg [based on dosing weight] as a single dose) | Intra- operative redosing for normal renal function every 6 hrs Intraopera tive redosing for normal renal function every 8 hrs | | Guidelines Network. Antibiotic prophylaxis in surgery. www.sign.ac.uk/pdf/si gn104.pdf CHOC Children's Antibiotic Prophylaxis for Surgery Guideline 2017. | Note that current protocol is only applicable to patient> 1 year old |

| PAEDIATRIC SURGERY | PR | PREFERRED FIRST LINE | | | F MAJOR REACTION TO BETA- LACTAMS++ | | | REFERENCES | REMARKS |
|---|--|---|--|--|--|--|--|--|--|
| GASTROINTESTINAL Biliary, including lap cholecystectomy | _ | 30 mg/kg (2 gm, 3 g for pts ≥ 120 kg. ary: acute cholecy Il bladder, obstruc | | Clindamycin p Clindamycin Gentamicin | • | Intraoperative redosing for normal renal function every 6 hrs Intraoperative redosing for normal renal function every 8 hrs | | Bratzler et al. 2013. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health-Syst Pharm.2013;70:195- 283. Berrios-Torres SI, Umscheid CA, Bratzler DW, et al. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. JAMA Surg. Published online May | Note that current protocol is only applicable to patient> 1 year old |
| GASTROINTESTINAL Colorectal** Appendectomy or ruptured viscus | Cefazolin plus Cefazolin Metronidazo | a Metronidazole 30 mg/kg (2 gm, 3 g for pts ≥ 120 kg. Die 15 mg/kg (500 mg) | Intra- operative redosing for normal renal function every 4 hrs Intra- operative redosing for normal renal function every 6 hrs | Clindamycin p Clindamycin Gentamicin | 10 mg/kg (900 mg) 2.5 mg/kg [based on dosing weight] (5 mg/kg [based on dosing weight] as a single dose) | Intraoperati ve redosing for normal renal function every 6 hrs Intraoperati ve redosing for normal renal function every 8 hrs | | 2017.090 cu is to | Note that current protocol is only applicable to patient> 1 year old |

| PR | EFERRED FIR | ST LINE | IF MAJOR REA | ACTION TO BET | TA- LACTAMS | DURATION | REFERENCES | REMARKS |
|-----------|--|--|---|--|--|--|---|--|
| | | | Vancomycin o | ^r Clindamycin | 1 | | | |
| Cefazolin | 30 mg/kg (2 gm, 3 g for pts ≥ 120kg | Intra-operative redosing for normal renal function every 4 hrs | Vancomycin | 15 mg/kg (15 mg/kg) | Intra- operative redosing for normal renal function | | CHOC Children's Antibiotic Prophylaxis for Surgery Guideline 2017. | Note that current protocol is only applicable to patient> 1 year old |
| | | | Clindamycin | 10 mg/kg (900 mg) | every 6 hrs Intra- operative redosing for normal renal function every 6 hrs | | | |
| | | | | | | | | |
| | | Cefazolin 30 mg/kg (2 gm, 3 g for pts ≥ 120kg | (2 gm, redosing for 3 g for pts normal renal ≥ 120kg function every 4 hrs | Cefazolin 30 mg/kg Intra-operative (2 gm, redosing for 3 g for pts normal renal ≥ 120kg function every 4 hrs Vancomycin of Vancomycin Vancomycin Vancomycin Vancomycin Vancomycin Vancomycin | Cefazolin 30 mg/kg Intra-operative (2 gm, redosing for 3 g for pts ≥ 120kg function every 4 hrs Clindamycin or Clindamycin Vancomycin or Clindamycin (15 mg/kg) (15 mg/kg) Clindamycin 10 mg/kg | Cefazolin 30 mg/kg Intra-operative (2 gm, redosing for 3 g for pts ≥ 120kg • cevery 4 hrs Clindamycin or Clindamycin Vancomycin or Clindamycin Vancomycin or Clindamycin Vancomycin or Clindamycin 15 mg/kg Intra-operative mg/kg) redosing for normal renal function every 6 hrs Clindamycin 10 mg/kg Intra-operative redosing for normal renal function | Cefazolin 30 mg/kg Intra-operative (2 gm, redosing for 3 g for pts ≥ 120kg function every 4 hrs Clindamycin Cefazolin 30 mg/kg Intra-operative (15 mg/kg Intra-operative mg/kg) redosing for normal renal function every 6 hrs Clindamycin Clindamycin 15 mg/kg Intra-operative mg/kg) redosing for normal renal function every 6 hrs Clindamycin 10 mg/kg Intra-operative mg/kg) redosing for normal renal function | Cefazolin 30 mg/kg Intra-operative (2 gm, redosing for 3 g for pts 2 120kg function every 4 hrs Clindamycin Clindamycin Vancomycin or Clindamycin 15 mg/kg Intra- (15 operative mg/kg) redosing for normal renal function every 6 hrs Clindamycin 10 mg/kg Intra- (900 mg) operative redosing for normal renal function every 6 hrs Intra- (900 mg) operative redosing for normal renal function 10 mg/kg Intra- (900 mg) operative redosing for normal renal function |

| PAEDIATRIC SURGERY | PREF | ERRED FIRST I | LINE | IF MAJOR REA | ACTION TO BETA | - LACTAMS | DURATION | REFERENCES | REMARKS |
|-----------------------|---|---|--|---------------|---|--|---|---|--|
| GYNECOLOGIC | Cefazolin OR Am plus Gentamicin Cefazolin | • | Intra-operative redosing for normal renal function every 4 hrs | Clindamycin p | lus Gentamicin 10 mg/kg (900 mg) | Intra- operative redosing for normal renal function | No additional antibiotic doses are needed for clean, clean-contaminated procedures, | CHOC Children's Antibiotic Prophylaxis for Surgery Guideline 2017. | Note that current protocol is only applicable to patient> 1 year old |
| | Ampicillin/ Sulbactam Metronidazole | 50 mg/kg (2 gm) of ampicillin component 15 mg/kg (500 mg) | Intra-operative redosing for normal renal function every 6 hrs | Gentamicin | 2.5 mg/kg [based on dosing weight] (5 mg/kg [based on dosing weight] as a | every 6 hrs Intra- operative redosing for normal renal function every 8 hrs | even in presence of a drain | | |
| | Gentamicin | 2.5 mg/kg [based on dosing weight] (5 mg/kg [based on dosing weight] as a single dose) | Intra-operative redosing for normal renal function every 8 hrs | | single dose) | | | | |

| PAEDIATRIC SURGERY | PREF | ERRED FIRST L | INE | IF MAJOR REA | ACTION TO BETA | - LACTAMS | DURATION | REFERENCES | REMARKS |
|------------------------------|---|--|--|----------------------|--|--|--|---|----------------------------|
| GENITOURINARY Bladder | For high risk only ***High risk gen | itourinary: urine | | Clindamycin p | lus Gentamicin | 1 | For other procedures, | CHOC Children's | Note that current protocol |
| augmentation, pyeloplasty | positive or unavailable, preoperative catheter, transrectal prosthetic biopsy, placement of prosthetic material Cefazolin OR Ampicillin plus Metronidazole plus Gentamicin | | Clindamycin | 10 mg/kg (900 mg) | Intra- operative redosing for normal renal | discontinue within 24 hrs of surgical end time | Antibiotic Prophylaxis for Surgery Guideline 2017. | is only applicable to patient> 1 year old | |
| | Cefazolin | 30 mg/kg (2 gm, 3 g for pts ≥ 120 kg. | Intra- operative redosing for normal renal function every 4 hrs | Gentamicin | 2.5 mg/kg [based on dosing weight] (5 mg/kg [based on dosing weight] as a single dose) | function every 6 hrs Intra- operative redosing for normal renal function every 8 hrs | | | |
| | Ampicillin/ Sulbactam | 50 mg/kg (2 gm) of ampicillin component | | | | | | | |
| | Metronidazole | 15 mg/kg (500 mg) | Intra- operative redosing for normal renal function every 6 hrs | | single dose; | | | | |
| | Gentamicin | 2.5 mg/kg [based on dosing weight] (5 mg/kg [based on dosing weight] as a single dose) | Intra- operative redosing for normal renal function every 8 hrs | | | | | | |

15. INTERVENTIONAL RADIOLOGY

| INTERVENTIONAL RADIOLOGY PROCEDURES | PREFERRED FIRST LINE | ALTERNATIVE IF ALLERGY | DURATION | REFERENCES | REMARKS |
|---|--|---------------------------|----------|--|--|
| Central Venous Access | | | | Venkatesan AM, Kundu S, | |
| 1. Chemoport | IV Cefuroxime 1.5gm | | 1 dose | Sacks D, et al. Practice | |
| 2. Perm Catheter | IV Cefuroxime 1.5gm | | 1 dose | Guideline For Adult Antibiotic Prophylaxis During Vascular | |
| Percutaneous Drainage 1. PTBD | IV Cefuroxime 1.5gm & IV Metronidazole 500mg | | 1 dose | And Interventional Radiology Procedures. J Vasc | |
| Ureteric stenting and Nephrostomy | IV Co-AmoxiClav 1.2g | | 1 dose | Interv Radiol. 2010; 21:1611–30. | |
| 3. Abscess drainage | IV Co-AmoxiClav 1.2g | | 1 dose | | |
| Embolization 1. Post TACE | Tab Metronidazole 400mg & Tab Co-AmoxiClav625mg | | 1 dose | | Review duration in diabetics and history of ERCP |
| 2. Uterine Artery Embolization | Co-AmoxiClav | | 1 dose | | |
| 3. Prostate Artery Embolization (Kidney + Bladder) | Co-AmoxiClav | | 1 dose | | |
| Stent Replacement 1. EVAR/TEVAR/Iliac or Large Vessel Stenting | IV Co-AmoxiClav 1.2g | | 1 dose | | |
| Tumour Ablation 1. Microwave Ablation or RFA Ablation > 3cm | Co-AmoxiClav& Metronidazole | | 1 dose | | |

Others:

| INT | ERVENTIONAL RADIOLOGY PROCEDURES | Antibiotic Prophylaxis | | |
|-------------|----------------------------------|------------------------|--|--|
| Neuro | | | | |
| Cerebral | Diagnostic | Not indicated | | |
| | Stenting | Indicated | | |
| | Embolisation | Indicated | | |
| | Stenting assisted coiling | Indicated | | |
| Head & Neck | Diagnostic | Not indicated | | |
| | Embolisation | Indicated | | |
| Spine | Diagnostic | Not indicated | | |
| | Embolisation | Indicated | | |
| | PTBD Diagnostic | Indicated | | |
| | PTBD stent | Indicated | | |
| | TACE | Indicated | | |
| | TACE DC Beads | Indicated | | |
| | Hepatic diagnostic | Not indicated | | |
| Oncoloni | Hepatic embolisation | Indicated | | |
| Oncology | Mesentric diagnostic | Not Indicated | | |
| | Mesenteric embolisation | Indicated | | |
| | RFA(Needle) | indicated | | |
| | SIRT Y90 | Indicated | | |
| | RFA (CRYO) | - | | |
| | | | | |

| INTE | RVENTIONAL RADIOLOGY PROCEDURES | Antibiotic Prophylaxis | | | | |
|---------------|----------------------------------|------------------------|--|--|--|--|
| Peripheral | TEVAR | - | | | | |
| Vascular | EVAR | - | | | | |
| | C. Venogram Diagnostic / Plasty | Not indicated | | | | |
| | Venogram Diagnostic /Plasty | Not indicated | | | | |
| | Upper Limb Sclerotherapy/EMBO | - | | | | |
| | Lower Limb Diagnostic/Plasty | Not indicated | | | | |
| | Lower Limb Sclerotherapy/EMBO | Indicated | | | | |
| | Uterine Artery Diagnostic | Not indicated | | | | |
| | Uterine Artery Embolisation | Indicated | | | | |
| | Thoracic Diagnostic | Not indicated | | | | |
| | Thoracic Embolisation | Indicated | | | | |
| | Aortogram | Not indicated | | | | |
| Venous Access | CVL insertion | Indicated | | | | |
| | Permanent Catheter/ Readjustment | Indicated | | | | |
| | Chemoport insertion/ removal | Indicated | | | | |
| | Cathetogram | - | | | | |
| | PICC | Indicated | | | | |
| | IPSS/IPVS | Not indicated | | | | |
| | AVS | Not indicated | | | | |
| | IVC Filter / Removal | Not indicated | | | | |
| | IJC Insertion | Indicated | | | | |
| Urology/Neph | Renal Angio | Not indicated | | | | |
| rology | Renal or Prostate Embolisation | Indicated | | | | |
| | Nephrostomy | Indicated | | | | |
| | Antegrade Stenting | Indicated | | | | |
| | Fistulogram Diagnostic/Plasty | Not indicated | | | | |
| | Mechanical Thrombectomy | Not indicated | | | | |

Timing of administration preoperative and intraoperative Surgical Antibiotic Prophylaxis (SAP)

Wan Rahiza Wan Mat

SAP refers to the prevention of infectious complications by administering an antimicrobial agent before exposure to contamination during surgery. Successful SAP requires delivery of the antimicrobial agent in effective concentrations to the operative site through intravenous administration at the appropriate time.

- Factors influencing the effectiveness of the SAP:
 - The underlying condition(s) of the individual patient (e.g., body mass index, or renal or liver function)
 - The time needed to complete the procedure
 - In additional to the classification of operation, the duration of surgery is positively associated with risk of wound infection.
 - Redosing may be considered when the procedure exceeds the half-life of the prophylactic antimicrobial agent or is longer than 3-4 hours
 - The half-life of the agent used
 - Antibiotic prophylaxis administered too late or too early reduces the efficacy of the antibiotic and may increase the risk of SSI.
 - Antibiotics with shorter half-life should be administered closer to incision time.
 (See PPUKM Surgical prophylaxis: Half-life of and proposed redosing interval of antibiotic).
 - The protein binding of the antibiotic should be taken into account to achieve adequate serum and tissue concentrations at the surgical site at the time of incision and up to wound closure—in particular to prevent incisional SSI.
 - Optimum time to administer SAP
 - SAPs should be given prior to and as closest to time of incision as practically possible.
 - WHO recommends administration of SAP not more than 120 minutes prior to skin incision and CDC recommends the exact time for SAP administration prior to incision is determined by the half-life of the antimicrobial. (See PPUKM Surgical prophylaxis: Half-life of and proposed redosing interval of antibiotic).
 - Intraoperative redosing of SAP
 - The precise effects of blood loss and fluid replacement are difficult to predict.
 - It will depend upon the particular antibiotic used, the time and rate of blood loss and fluid replacement.
 - Serum antibiotic concentrations are reduced by blood loss and fluid replacement, especially in the first hour of surgery when drug levels are high.
 - WHO recommends redosing if the duration of the procedure exceeds two half-lives of the drug, or if there is excessive blood loss during the procedure.
 - Redosing may be indicated for longer surgery or shorter-acting agents to maintain activity for the duration of the operation.
 - Redosing should be done after fluid replacement:
 - 1. Adult: Intraoperative Blood loss > 1.5L
 - 2. Children: Intraoperative Blood loss 25mL/kg

- Highlight for certain surgical procedures
 - Caesarean section:
 - In elective surgeries, CDC strongly recommends to administer SAP prior to skin incision.
 - In emergency surgeries, if time permits, to still administer SAP prior to skin incision. In instances when tine is limited, SAP is still effective given after cord clamping.
 - There was evidence of a significant reduction in maternal hospital stay among women receiving antibiotics preoperatively compared with women receiving it during caesarean section (MD -0.17, 95% CI -0.30 to -0.04; 2 trials, 1342 women).

Half-life of and proposed redosing interval of antibiotic

Chee Lan Lau

| Antimicrobial | Half-life in Adults (hours) Normal Renal Function | Recommended Redosing Interval (hours) From Initiation of Preoperative Dose [In normal renal function] |
|---------------------------------|--|---|
| Co-AmoxiClav | 1-1.3 | 4* |
| [Amoxicillin/ Clavulanic acid) | | |
| Ampicillin/ Sulbactam | 0.8 - 1.3 | 4* |
| Cefazolin | 1.2 - 2.2 | 4 |
| Cefuroxime | 1 - 2 | 4 |
| Ceftriaxone | 5.4-10.9 | NA |
| Clindamycin | 2 - 4 | 6 |
| Gentamicin | 2 - 3 | N/A |
| Vancomycin | 5 - 11 | N/A |
| Fluconazole | 30 | N/A |
| Metronidazole | 6 - 8 | N/A |

^{*}Redosing according to prolonged procedures.

References:

- 1. Bratzler et al. 2013. Clinical practice guidelines for antimicrobial prophylaxis in surgery. American journal of health-system pharmacy. 2013;70:195-283.
- 2. WHO Guidelines for the Prevention of Surgical Site Infection see http://www.who.int/gpsc/ssi-guidelines/en/index.html www.thelancet.com/infection Vol 16 December 2016
- 3. Scottish Intercollegiate Guidelines Network (SIGN). Antibiotic prophylaxis in surgery. Edinburgh: SIGN; 2008. (SIGN publication no.104). [July 2008, Updated April 2014]. Available from URL: http://www.sign.ac.uk
- 4. WHO recommendations for the prevention and treatment of maternal peripartum infections. World Health Organization, Geneva; 2015
 http://www.who.int/reproductivehealth/publications/maternal_perinatal_health/peripartum-infections-guidelines
- **5.** Kasatpibal Nongyao, Whitney Joanne D., Dellinger E. Patchen, Nair Bala G., and Pike Kenneth C.. Failure to Redose Antibiotic Prophylaxis in Long Surgery Increases Risk of Surgical Site Infection. Surgical Infections. May 2017, 18(4): 474-484. https://doi.org/10.1089/sur.2016.164
- 6. <u>Berríos-Torres SI</u>¹ et al. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. <u>JAMA Surg.</u> 2017 May 3.

Duration of Surgical Antibiotic Prophylaxis

Isa Naina Mohamed & Chee Lan Lau

A systematic review of 69 randomized control trials was conducted by Allegranzi et al(2016) and concluded that there was no additional benefit in prolonging antibiotic prophylaxis compared to single dose (OR 0.89; 95% CI: 0.77 to 1.03), except in cardiac and orthognathic surgeries. Berríos-Torres et al (2017) also evaluated 45 randomized control trials in cardiac; thoracic; vascular; ear, nose and throat, gynecologic, orthopedic, and general surgical procedures, and concluded that continuing antibiotic prophylaxis after surgical incision closure was not beneficial.

Furthermore, Allegranzi et al performed a meta-analysis of 7 randomized control trials which showed that prolonged antibiotic prophylaxis in the presence of a wound drain has no benefit in reducing SSI compared with perioperative prophylaxis alone (OR 0.79; 95% CI: 0.53 to 1.20). Therefore antibiotic should not be continued in the presence of wound drain. Berríos-Torres et al (2017) also strongly recommended the same for clean and clean-contaminated procedures with drain as well as prosthetic joint arthroplasty patients who are on systemic corticosteroids or immunosuppressive therapy.

Reference:

- Allegranzi et al 2016 WHO Guidelines for the Prevention of Surgical Site Infection see http://www.who.int/gpsc/ssi-guidelines/en/index.html www.thelancet.com/infection Vol 16 December 2016
- 2. <u>Berríos-Torres SI</u> et al. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. <u>JAMA Surg.</u> 2017 May 3. doi: 10.1001/jamasurg.2017.0904.

Implementing the guideline

Isa Naina Mohamed, Chee Lan Lau, Nordiah Hj Awang Jalil

Key Indicators

- Data Source :
 - HCTM PPUKM OT Schedule database, OT forms, Bed Head Tickets, Post op notes

Process measure

- 1. Was prophylaxis given for an operation included in local guidelines?
- 2. If prophylaxis was given for an operation not included in local guidelines, was a clinical justification for?
- 3. Prophylaxis recorded in the OT schedule notes?
- 4. Was the first dosage of prophylaxis given within 120 minutes of the start of surgery?
- 5. Were the **choice**, **dosage** and **route** of administration consistent with local guidelines for that procedure?
- 6. Was intraoperative antibiotic repeated in operation longer than 4 hours or when there is blood loss> 1.5L?
- 7. Was the post-operative antibiotic order and duration stated in the Post-Op notes?
- 8. Was the duration of prophylaxis greater than 24 hours [48 hours for Cardiothoracic surgery]?

Measurement for process 4 to 8:

Starting point: Surgical Incision; End point: last administration of antibiotic

2. Outcome measure [surveillance data from Infection control]

Surgical site infection rate

Surgical infection identified through post discharge surveillance at <= 30 days or 31 -90 days post operatively

- 1. **Surgical site infection rate**=number of SSIs occurring postoperatively vs total number of operative procedures.
- 2. **Rate of SSIs** occurring postoperatively in patients who receive **prophylaxis** compliant with guideline (as defined in the guideline) compared with rate of this infection in patients who receive prophylaxis noncompliant with guideline, expressed as a ratio.

Limitation:

- a. Patient usually come back as outpatient
- b. no cultures (only those with wound breakdown and admitted to hospital are taken cultures)

Reference:

- Barnaby et al. 2011, Nonconcordance With Surgical Site Infection Prevention Guidelines And Rates
 Of Surgical Site Infections For General Surgical Neurological, And Orthopedic Procedures,
 Antimicrobial Agents And Chemotherapy P. 4659–4663 Vol. 55, No. 10.
- 2. Janine Zweigner, Anna-Pelagia Magiorakos, Lea-Maxie Haag, Sabine Gebhardt, Elisabeth Meyer, Petra Gastmeier.2013, European Centre for Disease Prevention and Control. Systematic review and evidence-based guidance on perioperative antibiotic prophylaxis. Stockholm: ECDC
- PREVENT SURGICAL SITE INFECTIONS Getting Started Kit. Available at http://www.patientsafetyinstitute.ca/en/toolsResources/Pages/SSI-resources-Getting-Started-Kit.aspx

Surgical Procedures and Common Organisms

Mei Kuen Yin

| Surgical Site | Common pathogen | | | |
|--|---|--|--|--|
| Cardiac procedures: coronary artery bypass, | Staphylococcus aureus, S. epidermidis | | | |
| cardiac device insertion procedures (e.g., | | | | |
| pacemaker implantation), placement of ventricular | | | | |
| assist devices | | | | |
| Gastroduodenal | Enteric gram-negative bacilli, gram-positive cocci | | | |
| Biliary tract surgery (including pancreatic procedures) | Enteric gram-negative bacilli, enterococci, clostridia | | | |
| Appendectomy | Enteric gram-negative bacilli, anaerobes, enterococci | | | |
| Small intestine surgery | | | | |
| -Nonobstructed | Enteric gram-negative bacilli, gram-positive cocci | | | |
| Nonobstructed | Enteric gram-negative bacilli, anaerobes, | | | |
| -Obstructed | enterococci | | | |
| obstructed . | | | | |
| Hernia repair | Aerobic gram-positive organisms | | | |
| Colorectal | Enteric gram-negative bacilli, anaerobes, | | | |
| | enterococci | | | |
| Genitourinary | Enteric gram-negative bacilli, enterococci | | | |
| Gynaecologic and obstetric | Enteric gram-negative bacilli, anaerobes, group B Streptococcus, enterococci. | | | |
| head and neck | | | | |
| Clean with placement of prosthesis | Staphylococcus aureus, S. epidermidis, | | | |
| (excludes tympanostomy tube placement) | streptococci | | | |
| Clean-contaminated | Anaerobes, enteric gram-negative bacilli, S. aureus | | | |
| Neurosurgery | Staphylococcus aureus, S. epidermidis | | | |
| | | | | |
| Elective craniotomy | | | | |
| Cerebrospinal fluid shunting procedures | | | | |
| Implantation of intrathecal pumps | | | | |
| Orthopaedic | | | | |
| Clean operation involving hand, knee, or | N/A | | | |
| foot with no implantation of foreign material | 1970 | | | |
| Spinal procedures | Staphylococcus aureus, Staphylococcus | | | |
| Hip fracture | epidermidis | | | |
| - Tilp Hacture | 96.991111919 | | | |

| Internal fixation | |
|--|--|
| Total joint replacement | |
| | Common notheren |
| Surgical Site | Common pathogen |
| thoracic (noncardiac) | |
| lobecotomy, pneumonectomy, lung resection, thoracotomy | Staphylococcus aureus, S. epidermidis, streptococci, enteric gram-negative bacilli |
| vascular | |
| Arterial surgery involving a prosthesis, the abdominal aorta, or a groin incision | Staphylococcus aureus, S. epidermidis, enteric gram-negative bacilli |
| Lower extremity amputation for ischemia | S. aureus, S. epidermidis, enteric gram-negative bacilli, clostridia |
| percutaneous procedures | S. aureus, S. epidermidis |
| Angiography, angioplasty, thrombolysis, arterial closure device placement, stent placement Endograft placement Superficial venous insufficiency treatment IVC filter placement Tunnelled central venous access | |
| Breast | |
| Reduction mammoplasty Mammoplasty Lumpectomy Mastectomy Axillary node dissection | N/A |
| Breast cancer procedures Peference: Peference: | Staphylococcus aureus, S. epidermidis, streptococci* |

Reference:

- 1. Antimicrobial prophylaxis for surgery. Med Lett Drugs Ther 2016; 58:63.
- 2. Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect (Larchmt) 2013; 14:73.
- 3. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 2013; 70:195.
- 4. ACOG practice bulletin No. 195: Prevention of infection after gynecologic procedures. Obstet Gynecol 2018; 131:e172.
- 5. ACOG practice bulletin No. 120: Use of prophylactic antibiotics in labor and delivery. Obstet Gynecol 2011;117:1472.
- 6. Venkatesan AM, Kundu S, Sacks D, et al. Practice guideline for adult antibiotic prophylaxis during vascular and interventional radiology procedures. J Vasc Interv Radiol 2010; 21:1611.

Antibiotic Spectra among common clinical isolates

Ramliza Ramli & Mei Kuen Yin

| Microorganism | Ampicillin/sulbactam | Co Amoxi Clav | Cefazolin | Cefuroxime | Ceftriaxone | Clindamycin | Erythromycin |
|--------------------------|----------------------|---------------|-----------|------------|-------------|-------------|--------------|
| MSSA | + | + | + | + | + | | + |
| MRSA | | | | | | | |
| CONS | | | V | | | | |
| Streptococcus sp | | | | NT | | | + |
| Streptococcus pneumoniae | | | | NT | | | + |
| Enterococcus faecalis | | | | 0 | | | NT |
| Enterococcus faecium | | | | | | | |
| Enterococcus sp | | | | | | | |
| Acinetobacter | V | NT | | NT | | | |
| Enterobacter | | + | | + | | | |
| Escherichia coli | | + | | + | | | |
| Klebsiella | | + | | + | | | |
| Proteus mirabilis sp | | + | | + | | | |
| ESBL | | 0 | | 0 | | | |
| Amp-C producer | | | | | | | |

| Ab | Abbreviations: | | | | | | |
|----|-----------------------------------|--|--|--|--|--|--|
| + | > 60% | | | | | | |
| ٧ | 30-60% | | | | | | |
| 0 | <30% | | | | | | |
| | synergistic when used with a beta | | | | | | |
| S | lactam | | | | | | |

